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Chapter 1. 
Introduction. 
Schizophrenia psychopathology. 
 
Schizophrenia is a chronic, severe, and disabling mental disorder, with a global lifetime 
prevalence of about 0.3–0.7%. Schizophrenia is characterized by a disintegration of 
thought processes and of emotional responsiveness. Symptoms are classified in positive 
symptoms, such as auditory hallucinations, paranoid or bizarre delusions, and 
movement disorders (agitation or catatonia); in negative and cognitive symptoms such 
as blunted affect, alogia, anhedonia (inability to experience pleasure), working memory 
impairment, significant social withdrawal and vocational dysfunction. The onset of 
symptoms typically occurs in young adulthood (20–28 years for males and 26–32 years 
for females), with a pre-onset phase of the illness, characterized by transient or self-
limiting psychotic symptoms and the non-specific symptoms of social withdrawal, 
irritability, dysphoria. In patients with a first episode of psychosis a good long term 
outcome occurs in about 42%, an intermediate outcome in 35% and a poor outcome in 
27%. 
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The Dopaminergic Hypothesis of Psychosis. 
Dysfunctions in dopamine and glutamate neurotransmissions, as well as in their 
interplay, have been suggested in the pathophysiology of psychosis (de Bartolomeis et 
al. 2005).  
In its more traditional postulation, the dopaminergic hypothesis of psychosis states that 
putative subcortical hyperdopaminergy, stemming from overactivation of meso-striatal 
pathways, may cause productive psychotic symptoms (Kapur 2004). 
Several lines of evidence confirm the involvement of the dopamine system in the 
pathophysiology and therapy of psychosis and seem to corroborate the dopaminergic 
hypothesis of psychosis: 1) dopamine-agonists, such as amphetamine, exerts a 
psychotomimetic action; amphetamine increases striatal dopamine levels, triggers 
psychotic symptoms or worsens psychotic symptoms in schizophrenic patients 
(Lieberman et al. 1987; Howes and Kapur 2009); 2) schizophrenic subjects exhibit 
increased striatal release of dopamine after injection of amphetamine compared to 
healthy volunteers as demonstrated by in vivo positron emission tomography (Breier et 
al. 1997); 3) the most effective compounds against psychotic symptoms, the so-called 
antipsychotic agents, used since 1952 (Delay et al. 1952), share dopamine D2 receptor 
(D2R) antagonist properties (Snyder 1976) and increase the dopamine metabolism in rat 
brain (Carlsson and Lindqvist 1963); 4) therapeutic efficacy of antipsychotics is tightly 
correlated to the degree of affinity and blockade of dopamine D2Rs (Creese et al. 1976). 
A subsequent refinement of the dopaminergic hypothesis of psychosis has hypothesized 
that a decreased function of the dopaminergic neurons belonging to the meso-cortico-
limbic tract may explain the cognitive dysfunctions that are observed in schizophrenia. 
This view has been called the “cortical hypodopaminergia hypothesis” (Kapur 2004) 
and has been suggested to explain.  
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The dopaminergic hypothesis ascribes positive symptoms of schizophrenia 
(suspiciousness, persecution and grandiosity delusions and hallucination) to presynaptic 
striatal hyperdopaminergia D2R mediated, and negative (depression, flattened affect, 
social withdrawal) and cognitive symptoms (cognitive impairment, disorganized 
thinking, autistic behaviors) to prefrontal hypodopaminergia D1-receptor (D1R) 
mediated (Pycock et al. 1980; Scatton et al. 1982; Carlsson 1988; Davis et al. 1991; 
Abi-Dargham et al. 2002; Davidson and Heinrichs 2003; Goldman-Rakic et al. 2004; 
Tamminga 2006; Howes and Kapur 2009; Javitt 2010). Preliminary data in preclinical 
settings have been confirmed by PET and SPECT studies that have observed an increase 
in blood flow in the striatum (Laruelle et al. 1996; Breier et al. 1997; Abi-Dargham et 
al. 1998) and a decrease in blood flow in cortical areas of psychotic patients (Erritzoe et 
al. 2003). 
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Glutamatergic Mechanisms of Psychosis: relevance for preclinical Animal Model 
of Psychosis. 
Since 1950s, Phencyclidine (PCP) has been observed to exacerbate psychotic symptoms 
in schizophrenic individuals and to induce a schizophrenia-like state in healthy subjects  
characterized by hostility, agitation, auditory hallucinations, and paranoic delusions 
(Allen and Young 1978). In 1980s, PCP was characterized as a non-competitive 
antagonist of the glutamate  N-Methyl-D-Aspartate-Receptor (NMDA-R) (Lodge and 
Anis 1982; Javitt 1987; Javitt and Zukin 1991); implying the possibility that 
glutamatergic neurotransmission also may be implicated in the pathophysiology of 
psychosis. In 1990s, another non-competitive NMDA-R antagonist, ketamine, was 
described to induce in healthy volunteers a psychotic-state mimicking positive, negative 
and cognitive symptoms of schizophrenia (Javitt and Zukin 1991; Krystal et al. 1994; 
Adler et al. 1999; Heresco-Levy 2003; Krystal et al. 2003; Javitt 2010) and to 
exacerbate psychotic symptoms in both drug-free schizophrenic patients (Malhotra et al. 
1997; Lahti et al. 2001; Heresco-Levy 2003) and in remitted patients (Lahti et al. 1995; 
Heresco-Levy 2003). The occurrence of negative symptoms in non-schizophrenic 
individuals had not been observed in other models of schizophrenia, rendering 
glutamatergic drugs-induced psychosis the best pharmacological model of disease in all 
its psychopathological manifestations.  
Concomitant with clinical reports that non-competitive antagonists at NMDA-R may 
induce a schizophrenia-like psychosis, several animal studies were carried out to 
evaluate neuropathological and behavioral abnormalities in rats exposed to selective 
antagonists at NMDA-R (Carlsson and Svensson 1990; Tiedtke et al. 1990; Riederer et 
al. 1991; Schmidt et al. 1991). Neurodegenerative changes in corticolimbic regions of 
rat brains were associated with competitive or non-competitive blockade of NMDA-R 
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(Olney and Farber 1995). An acute vacuole reaction in neurons of the posterior 
cingulated and retrosplenial cortices was observed after a single low subcutaneous dose. 
Higher doses caused an extensive neuron-necrotizing reaction spreading to neurons in 
several additional neocortical and limbic brain regions (Allen and Iversen 1990; Olney 
et al. 1991; Sharp et al. 1994). 
Acute sub-anaesthetic doses of non-competitive NMDA-R antagonists were found to 
induce several behaviors in rodents mimicking schizophrenia, including 
hyperlocomotion, enhanced stereotyped behaviors, cognitive and sensorimotor gating 
deficits, and impaired social interactions (Lipska and Weinberger 2000).  
Thus, administration of non-competitive NMDA-R antagonists, as ketamine, may 
represent a powerful preclinical model of psychosis, with substantial heuristic properties 
to study both molecular targets in psychosis pathophysiology and novel therapeutic 
strategies (Lipska and Weinberger 2000). 
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The NMDA-R Hypofunction Hypothesis of Psychosis. 
The histopathological, biochemical, and behavioral studies quoted above were the basis 
for the Olney and Farber (Olney et al. 1999) model of psychosis pathophysiology 
known as the NMDA-R hypofunction (NRH) hypothesis.  
According to Olney & Farber hypothesis, hypofunction of NMDA-R may result in a 
decreased activation of GABAergic interneurons by collateral fibers of glutamatergic 
pyramidal neurons. Decreased activation of GABAergic interneurons result in a lack of 
inhibition of glutamatergic pyramidal neurons which increase their firing onto post-
synaptic neurons located in other cortical regions, in the striatum and the 
mesencephalon. This has been suggested to lead to cortical neurotoxicity, while 
increased firing upon subcortical dopaminergic neurons may activate in turn over these.  
NRH may thus lead to a complex cortical-subcortical network dysinhibition, involving 
several neurotransmitter systems (glutamatergic, cholinergic, serotoninergic, 
noradrenergic, GABAergic, dopaminergic), to a condition of excitotoxicity by hyper-
glutamatergy upon non-NMDA-R (Moghaddam et al. 1997; Adams and Moghaddam 
1998; Olney et al. 1999; Farber 2003; Krystal et al. 2003; Lisman et al. 2008) and to the 
dysinhibition of acetylcholine fibers from basal forebrain (Giovannini et al. 1994; Kim 
et al. 1999; Olney et al. 1999; Farber et al. 2002; Farber 2003). These biochemical 
dysfunctions may account for the histopathological and behavioral abnormalities seen in 
rodents. 
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The Dopamine- Glutamate Interplay in Psychosis and the Post-Synaptic Density. 
Dopaminergic and glutamatergic systems are tightly interconnected in the forebrain at 
both the cellular and the subcellular level. The imbalance of the dopamine-glutamate 
interplay may represent one of the key mechanism in psychosis pathophysiology. 
The prefrontal cortex (PFC) sends efferent glutamatergic projections to the nucleus 
accumbens and to other limbic areas (hippocampus and amygdale), which also modulate 
nucleus accumbens activity by glutamatergic projections (Grace 2007), and to 
dopaminergic neurons within ventrotegmental area (VTA) (Carr and Sesack 2000), 
which project to cortical and subcortical limbic areas. Dopamine neurons from the VTA 
and glutamate fibers from multiple cortical and subcortical areas, project to pyramidal 
glutamatergic neurons and GABA interneurons in the PFC. 
This afferent-efferent network integrates sensory and limbic information and control 
cognitive and motor behaviors. PFC is assumed to exert a top-down control over 
incoming information and goal-directed behavior and to regulate cognitive and 
executive processes involving emotion, memory, motivation, and control of goal-
directed behavior. The activation of NMDA-R on subcortical GABAergic neurons 
provides inhibitory control on excitatory glutamatergic thalamic fibers projecting to 
pyramidal neurons in the PFC. NRH on GABAergic neurons may cause a dysinhibition 
of glutamatergic thalamo-cortical neurons and may induce excessive stimulation of 
pyramidal neurons in the PFC. Indeed, PFC dysfunctions have consistently been 
described in schizophrenic patients (Krystal et al. 2003; Winterer and Weinberger 
2004). 
Moreover, dysfunctions of striatum have also been predicted to play a critical role in the 
pathophysiology of schizophrenia. Striatal neurons receive glutamatergic projections 
from prefrontal cortex, hippocampus, amygdala, and thalamus, belonging both to 
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sensory-motor and limbic systems; and dopaminergic projections from susbstantia nigra 
and VTA, constituting respectively the so-called meso-striatal and meso-limbic systems, 
which participate in the control of motor functions and in motivational aspects of 
behavior. Output projections from striatum are involved in the gating of information 
flow via thalamus to the prefrontal cortex.  
Possible consequences of an NRH-induced dysinhibition of excitatory pathways may 
include the dysinhibition of dopamine meso-striatal release,  that may explain positive 
symptoms; the inhibition of dopamine meso-cortical release on D1R that may explain 
negative symptoms; the inhibition of GABAergic inhibition on cortical-striatum-
pallidum-thalamus-cortical network that may explain behavioral and cognitive disorders 
(Olney and Farber 1995; Moghaddam et al. 1997; Olney et al. 1999; Farber 2003). 
Hyperdopaminergia may per se cause hyperinhibition of glutamate release, thus 
worsening a condition of NRH (Olney et al. 1999). It has been proposed that aberrant 
changes at different levels (primary NRH or NRH equivalent condition, such as 
dopamine hyperfunction or GABAergic hyperhinhibition) may ultimately result in 
presynaptic dopamine dysregulation that may be the final common pathway to induce 
an “aberrant attribution of salience” to cortical inputs (Olney et al. 1999; Kapur and 
Mamo 2003; Howes and Kapur 2009; Javitt 2010). Aberrant salience has been 
attributed to the dysregulation in dopamine transmission and may be explained as an 
aberrant interpretation of external or internal events: delusions and hallucinations 
become the  cognitive and perceptive explanation of these aberrant information (Kapur 
and Mamo 2003). 
In striatum, dopamine and glutamate fibers take connections with GABAergic   
interneurons, called the medium-sized spiny neurons (MSNs). MSNs take part to the 
recurrent neuronal loop starting from the cortex and driving inputs back to the cortex via 
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basal ganglia and thalamus. Therefore, dopaminergic and glutamatergic inputs on these 
GABAergic neurons appear to regulate the output signal starting from MSNs. At the 
subcellular level, dopamine and glutamate interplay occurs within an electrondense 
thickening located at the post-synaptic sites of glutamatergic synapse (Okabe 2007; 
Sheng and Hoogenraad 2007), called the Post-Synaptic Density (PSD), which is 
enriched in the dendritic spines of MSNs. PSD is a complex protein network devoted to 
the intracellular integration of synaptic signals and to the fine-tuning of signal 
transduction. The PSD is a protein machinery that integrates synaptic signals from 
presynaptic neurons and different neurotransmitter systems, including the dopaminergic 
and the glutamatergic (de Bartolomeis et al. 2005). The PSD has been described as a 
protein mesh which allows physical bridging and functional connection between a wide 
array of intracellular molecules involved in synaptic signal transduction, including 
scaffold proteins, surface receptors, cytoskeletric factors, effectors of the second 
messengers pathways. This complex ultrastructure is in continuous re-modeling in 
response to synaptic signals. Stable or transient changes of PSD proteins have been 
suggested to be implicated in the  pathophysiology of a number of neuropsychiatric 
diseases (de Bartolomeis and Iasevoli 2003; Szumlinski et al. 2006; Gardoni et al. 2009; 
Cheng et al. 2010). Moreover, we have observed that gene expression of PSD proteins 
may be modulated by antipsychotic drugs, implying that PSD may also be involved in 
the mechanism of action of these agents (Polese et al. 2002; de Bartolomeis and Iasevoli 
2003; Iasevoli et al. 2007; Iasevoli et al. 2010; Tomasetti et al. 2011). 
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PSD members and Immediate Early genes (IEGs). 
Homer. 
Homer proteins are a family of constitutive and inducible scaffold proteins of 
glutamatergic synapses, involved in signal transduction, modulation of local calcium 
dynamics, and neuronal development. In humans, Homer proteins, codified by different 
genes on different chromosomes: Homer 1 (chromosome 5q14.2), Homer 2 
(chromosome 15q24.3) and Homer 3 (chromosome 19p13.11), all of which exhibit 
numerous isoforms (Shiraishi-Yamaguchi and Furuichi 2007). Homer 1b/c (H1b/c), 
Homer 2a/b (H2a/b) and Homer 3a/b (H3a/b) are long Homer forms characterized by a 
conserved amino-terminal EVH1 domain that binds proline-rich sequences, and a 
carboxy-terminal coiled-coil domain that allows homo-multimerization. Homer proteins 
bind several targets within the PSD, including type I metabotropic receptors of 
glutamate (mGluR1α/5), the Inositol Trisphosphate-Receptor (IP3-R), ryanodine 
receptor, the NMDA-R scaffolding protein Shank, the transient receptor potential 
canonical-1 (TRPC-1), G-guanosine trisphosphatases (GGTPases), actin cytoskeleton, 
transcription factors such as NFTA and PAX6 (Szumlinski et al. 2006; Shiraishi-
Yamaguchi and Furuichi 2007; Foa and Gasperini 2009). 
In response to synaptic activity, Homer homomerics different target proteins in close 
proximity under the membrane, to facilitate the glutamate-mediate signal transduction 
and the cross-talking among different pathways; Homer declustering is induced by 
increasing of intracellular calcium through NMDA channels or voltage-dependent 
calcium channel (Szumlinski et al. 2006; Shiraishi-Yamaguchi and Furuichi 2007). 
Short forms of Homer, Homer 1a (H1a), Ania 3 (Ania3), Homer 2c/d (H2c/d), Homer 
3c/d (H3c/d) lack the carboxy-terminal coiled- coil domain, therefore they can not 
homo-multimerize. Once induced, these short isoforms may decouple long Homer-
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mediated homo-hetero-clusters. H1a and Ania3 behave as immediate early genes 
(IEGs), whose expression is induced by several neuronal stimuli, such as seizure, 
kindling, dopamine stimulation, long-term potentiation, psychoactive stimulants and 
drugs, exploration of novel environment, stimulation by light, sleep loss, learning 
activity (Bottai et al. 2002; Szumlinski et al. 2006; Shiraishi-Yamaguchi and Furuichi 
2007).  
In previous studies, it has been observed that the prototype “typical” antipsychotic 
haloperidol  triggers the expression of the inducible Homer1 variant Homer1a (de 
Bartolomeis et al. 2002). Homer1a expression has also been found induced by atypical 
antipsychotics, although with divergent quantitative and topographic patterns when 
compared to haloperidol (Ambesi-Impiombato et al. 2007; Iasevoli et al. 2009; Iasevoli 
et al. 2010). Moreover, Homer1a expression is significantly induced by administration 
of a compound with relative selective antagonism at dopamine D2Rs (Iasevoli et al. 
2009). Homers may thus represent adaptor molecules that facilitate cross-talk between 
the glutamatergic and dopaminergic systems and may be involved in the molecular 
mechanism by which dopaminergic compounds may modulate glutamatergic signaling.  
Intriguingly, Homer1 knock-out mice exhibited some schizophrenia-related phenotypes, 
including disrupted PPI, impaired working memory performance, increased locomotor 
response to MK-801 and amphetamine (Yuan et al. 2003; Szumlinski et al. 2005). 
These mice also showed increased levels of glutamate in the prefrontal cortex and 
decreased levels in the nucleus accumbens, consistent with the cortical 
hyperglutamatergic/striatal hypoglutamatergic state postulated in schizophrenia 
(Szumlinski et al. 2005). Moreover, a trend toward an association with schizophrenia 
has been described in a European population (Norton et al. 2003) and Homer1a mRNA 
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is overexpressed in the pharmacological animal model of psychosis provided by acute 
administration of subanaesthetic doses of ketamine (Iasevoli et al. 2007). 
 
PSD95. 
The Postsynaptic Density Protein 95 (PSD95), also known as Synapse-Associated 
Protein 90 (SAP-90), is a protein encoded by the DLG4 (disks large homolog 4) gene 
(Cho et al. 1992; Hunt et al. 1996; Stathakis et al. 1997). PSD95 is a member of the 
membrane- associated guanylate kinase (MAGUK) family. PSD95 has three PDZ C-
terminal domains, a SH3 domain and a guanylate kinase domain, but it lacks of ATP 
binding site, being catalytically inactive (Woods and Bryant 1993). It 
heteromultimerizes with PSD93. Recruiting this protein into the same postsynaptic sites 
to form a multimeric scaffold for the clustering of receptors, such as NMDA-R and 
AMPA-R, a Calcium-activated form of nitric oxide synthase, ion channels, such as 
potassium channel, and associated signaling proteins such as neuroligin and 
calmoduline (Hunt et al. 1996). Regulatory processes, such as phosphorylation, modify 
PSD95 and its ligand to determinate assembly or disassembly of macromolecular 
complexes (Gardoni et al. 2009). PSD95 regulates dendritic spine size and shape (Sala 
et al. 2005). Therefore, PSD95 influencing the glutamate downstream signals, may be 
involved in pathophysiology of psychosis (Hahn et al. 2006). 
 
Arc. 
Activity-Regulated Cytoskeleton-associated Gene (Arc) is a member of the immediate-
early gene family induced also in the presence of protein synthesis inhibitors (Link et al. 
1995; Lyford et al. 1995). The Arc gene is located on chromosome 8 in the human and 7 
in the rat, and it is highly conserved across vertebrate species. Arc proteins are localized 
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to activated synaptic sites in a NMDA-R dependent way (Steward and Worley 2001), 
has a spectrin homology sequence in C-terminal region, and binding sites for endophilin 
3 and dynamin 2. Arc interacts with proteins involved in clathrin-mediated endocytosis 
and facilitates the removal of AMPA-R from the membrane (Chowdhury et al. 2006; 
Bloomer et al. 2007). Indeed, Arc is a marker for neuronal plastic changes relevant for 
learning and memory (McIntyre et al. 2005). 
 
c-fos.  
Although not a member of PSD, c-fos has great relevance for molecular neuroimaging 
studies, as it represents a well studied marker of neuronal activity during behavioral 
procedures or after drug administration. c-fos is a cellular proto-oncogene belonging to 
the IEG family of Transcription Factors. c-fos protein has a leucine-zipper DNA 
binding domain, and a C-terminal transactivation domain, by which it can dimerize with 
c-jun to form the AP1 transcription factor. c-fos gene is up-regulated in response to 
many signals involved in proliferation and differentiation. In neuroscience, c-fos 
expression is an indirect marker of neuronal activity because c-fos is often expressed 
when neurons fire action potentials. Indeed, c-fos mRNA is upregulated in neuron 
exhibiting recent activity (Nichols and Sanders-Bush 2002; Day et al. 2008; 
VanElzakker et al. 2008). 
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Glutamatergic mechanisms of antipsychotic drugs and new antipsychotic 
compounds with glutamatergic action. 
Reports on glutamate involvement in psychosis raised the issue that drugs used in 
psychosis may also act on glutamatergic neurotransmission. A growing body of 
evidence is confirming that typical and atypical antipsychotics may exert, at least in 
part, an action on glutamatergic system. Typical and atypical antipsychotics modify 
extracellular level of glutamate, increase or decrease glutamate transporter and receptor 
gene expression and modify the glutamatergic receptors density as adaptive response of 
synapses (de Bartolomeis et al. 2005). However, antipsychotic agents acting primarily 
on glutamatergic neurotransmission are still lacking, most likely because of the risk of 
epileptogenesis and excitotoxicity with direct stimulation and/or blockade of glutamate 
receptors (Wasterlain and Chen 2008; Qian et al. 2011).  
Therefore, a number of compounds modulating, rather than activating or blocking 
glutamate receptors, are currently on examination. 
The NMDA-R is structurally complex and exhibits several modulation sites. Among 
them, the strychnine-insensitive glycine-binding site, by which the glutamate co-agonist 
glycine may positively modulate NMDA-R opening. Previous studies have explored the 
possibility to modulate NMDA-R function, facilitating glutamatergic neurotransmission 
by means of NMDA-Rs co-agonists (glycine, D-serine, D-cycloserine) or blocking the 
re-uptake of glycine on astrocyties through glycine transporter inhibitors (N-methyl 
glycine, called sarcosine).  
Recently, a class of compounds acting as selective antagonists at NR2 subunits by an 
allosteric interaction with NR2 extracellular domain has been described (Malherbe et al. 
2003). These compounds are predominantly selective for NR2B subunits and are 
derivatives of ifenprodil, the first selective NR2B allosteric antagonist described. 
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Ifenprodil-derivatives have been proposed in clinical trials in the therapy of traumatic 
brain injury. The polyamines spermine and spermidine act as positive allosteric 
modulators of NMDA-R by binding the so-called polyamine binding site. Polyamines 
facilitate NMDA-R function by a glycine-dependent (enhancement of receptor affinity 
for glycine) and a glycine-independent NR2B-dependent mechanism (Williams 1997). 
A positive allosteric modulation of NMDA-R has also been reported for the endogenous 
neurosteroid pregnenolone sulphate, which seems to act by NR2A and NR2b subunits 
(Malayev et al. 2002).  
Another class of compounds that has received great attention has been that of 
AMPAkines. AMPAkines are AMPA-R agonists that increase the peak and the duration 
of open-channel phase playing a role in starting the events responsible for synaptic 
plasticity as long-term potentiation mediated by NMDA-R activation. AMPAkines 
potentiate synergistically the activity of typical and atypical antipsychotics in blocking 
methamphetamine-induced locomotor activity and behavioral modifications in rats 
(Johnson et al. 1999). 
Another suggested strategy has been to modulate metabotropic glutamate receptors. 
mGluR5 is a postsynaptic receptor involved in neuron activation involved in 
depolarization, increases of NMDA-R currents, increases of firing frequency and burst-
firing activity (Awad et al. 2000). mGluR5 amplification of NMDA-R-mediated 
responses provides the basis to rescue NMDA-R hypo-glutamatergic neurotransmission. 
Positive allosteric modulators of mGluR5, such as ADX47273, prevent PCP- and 
amphetamine-induced hyperlocomotion (Liu et al. 2008).  
One of the most recent therapeutic strategies suggest to use glutamate release inhibitors 
(GRIs): antiepileptic drugs (above all lamotrigine and topiramate) (Dursun and 
Devarajan 2001; Tiihonen et al. 2003; Afshar et al. 2009); L-type calcium channel 
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antagonist (nimodipine); the mGluR2/3 agonist LY354740, that has been described to 
counteract ketamine-induced disruption of working memory in healthy humans (Krystal 
et al. 2005); inhibition of glutamate carboxipeptidase II (GCP-II). GCP-II is the enzyme 
that degrades the endogenous agonist of mGluR2/3, N-acetylaspartylglutamate 
(NAAG). Therefore inhibition of GCP-II may increase concentration of endogenous 
NAAG, thus representing a potential strategy for mGluR2/3 activation (Krystal et al. 
2003). 
Growing interests are captured also by the NMDA-R partial antagonist memantine 
(Krystal et al. 2003). Memantine- NMDA-R interaction allows physiological activation 
of NMDA-R and inhibits pathological over-activation of NMDA-R (Johnson and 
Kotermanski 2006). Indeed, memantine decreases in synaptic noise resulting from 
excessive NMDA-R activation, allows the physiological synaptic signaling and re-
balances between inhibition and excitation of glutamate system (Parsons et al. 1999; 
Parsons et al. 2007; Gilling et al. 2009). Memantine is approved by the Food and Drug 
Administration for treatment of moderate to severe Alzheimer Disease and is used in 
clinical practice for treatment of other neuropsychiatric disorder associated with 
excitotoxic cell death such as Parkinson’s disease, amyotrophic lateral sclerosis, 
epilepsy, stroke, spasticity, vascular dementia, in off-label use for psychosis. 
Memantine is also being tested for generalized anxiety disorder, depression, obsessive 
compulsive disorder, bipolar disorder, substance abuse, binge eating disorder, Attention 
Deficit Hyperactivity Disorder, pervasive developmental disorders (Zdanys and Tampi 
2008), Tourette Syndrome, HIV associated dementia, multiple sclerosis, glaucoma, 
neuropathic pain syndrome, opioid dependence, systemic lupus erythematous. 
Memantine reduces or prevents excitotoxic damage without producing undesired side 
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effects, such as hallucination, agitation, catatonia, centrally mediated increase in blood 
pressure, anesthesia (Zdanys and Tampi 2008). 
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Aims of the research.  
In the studies described herein, we explored in three different paradigms the expression 
of multiple genes relevant for dopamine and glutamate neurotransmission, glucose 
metabolism and brain region specific activation (i.e. activation of inducible early genes) 
in an animal model of psychosis, in which glutamatergic neurotransmission was 
perturbed by NMDA-R blockade or modulation following in vivo administration of sub-
convulsing and sub-anesthetic doses of ketamine. 
The overall strategy beyond this approach  stemmed mainly from the observation that in 
vivo human studies have shown in psychotic patients or in normal subject after 
ketamine administration a disruption of dopamine-glutamate interaction, an abnormal 
glucose metabolism in cortical and subcortical areas and a dysfunctional activation of 
cortico-striatal regions (Kegeles et al. 2002; Erritzoe et al. 2003). 
We chose NMDA-R blockade or modulation as putative animal model of psychosis not 
only on the basis of  the results from human studies  but also because previous studies 
have extensively shown that NMDA-R antagonism after administration of ketamine, is 
responsible of neuronal pathological changes in rat brain regions believed to be relevant 
in modeling the pathophysiology of schizophrenia. We chose NMDA-R blockade or 
modulation as putative animal model of psychosis not only on the basis of  the results 
from human studies  but also because previous studies have extensively shown that 
NMDA-R antagonism after administration of ketamine, is responsible of neuronal 
pathological changes in rat brain regions believed to be relevant in modeling the 
pathophysiology of schizophrenia (Prabakaran et al. 2004; McDermott and de Silva 
2005; Robey and Hay 2006; Martins-de-Souza et al. 2009; Martins-De-Souza et al. 
2010). 
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Considering the relevance of spatial analysis to gain insights in the molecular 
perturbation that putatively occurs after administration of ketamine, a molecular 
imaging approach at level of transcripts was using of radioactive quantitative in situ 
hybridization. 
Therefore, the animal model provided by NMDA-R blockade may allow studying 
molecular dysfunctional putatively implicated in psychosis pathophysiology.  
As NMDA-R blockade affects glutamatergic neurotransmission, it is expected that 
several other neurotransmitter systems, above all the dopaminergic may be affected by 
administration of this compound, thus raising the possibility to investigate the 
perturbation of the interplay between neurotransmitter systems. It has indeed suggested 
that psychosis, rather than depending on alteration in a single neurotransmitter system, 
may result from a complex imbalance between several systems, including the 
dopaminergic and the glutamatergic ones.  
The set of studies carried out and reported here has been specifically designed to 
investigate these issue. 
After having reported the experimental procedure (chapter 2). we will describe each 
specific experimental paradigm and corresponding results: 
a) Modulation of Hk1 and GLUT 3 in an animal model of psychosis: a putative 
link between metabolism and behavioral disorders (chapter 3). 
b) Modulation of Dopamine Receptors type 1-2 and Dopamine Transporter in an 
animal model of psychosis: acute and subchronic paradigms (chapter 4). 
c) Modulation of constitutive and inducible early genes implicated in glutamate 
neurotransmission by different antagonists at NMDA receptors (chapter 5). 
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Chapter 2. 
Experimental procedures. 
 
Animals and treatments. 
Male Sprague–Dawley rats (Charles-River Laboratories, Lecco, Italy) of approximately 
250- 300g were housed in a temperature and humidity controlled colony room.  
 
“Metabolic Genes”: rats were randomly assigned to one of the following treatment 
groups: (1) saline solution 0.9% NaCl (VEH); (2) Ketamine 12 mg/kg (KET12); (3) 
Ketamine 50 mg/kg (KET50). There were four rats for each treatment group. Animals 
were sacrificed by decapitation 180 minutes after the treatment.  
 
“Dopamine genes”:  
Acute paradigm: rats were randomly assigned to one of the following treatment groups: 
(1) saline solution 0.9% NaCl (VEH); (2) Ketamine 12 mg/kg (KET12); (3) Ketamine 
50 mg/kg (KET50). There were four rats for each treatment group. Animals were 
sacrificed by decapitation 180 minutes after the treatment.  
Subchronic paradigm: rats were randomly assigned to one of the following treatment 
groups: (1) saline solution 0.9% NaCl (VEH); (2) Ketamine 12 mg/kg (KET12) with 1 
injection/day per 7 days. There were four rats for each treatment group. Animals were 
sacrificed by decapitation 180 minutes after the last injection.  
 
“Postsynaptic density Genes”: on the day of the experiment, rats were randomly 
assigned to one of the five following groups: (1) saline solution 0.9% NaCl (VEH); (2) 
memantine 5 mg/kg (MEM); (3) MK-801 0.8 mg/kg; (4) ketamine 25 mg/kg (KET25); 
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(5) ketamine 50 mg/kg (KET50). Each experimental group was composed of seven rats. 
The animals were sacrificed by decapitation 90 minutes after the treatment. 
 
All drugs were dissolved in a vehicle of physiological saline solution (0.9% NaCl), 
which was used as a control. Drug doses were chosen based on previous animal studies 
in which molecular and behavioral effects predictive of either pro-psychotic or anti-
psychotic activity were elicited (Iasevoli et al. 2007; Parsons et al. 2007). Ketamine was 
administered in sub-anaesthetic doses (a mild-to-moderate sub-anaesthetic, 12 and 25 
mg/kg, and a high sub-anaesthetic and sub-convulsant dose, 50 mg/kg), known to 
provide an animal model of psychosis and to affect NMDA-R-mediated glutamate 
neurotransmission. Ketamine doses are in the range of those demonstrated to elicit 
behavioral effect as well as to induce early gene activation (Iasevoli et al. 2007). The 
dose of MK-801 is based on the behavioral and neurochemical effect both in acute and 
in chronic of this compound. 
The dose of memantine (5 mg/kg i.p.) in the rats was  the acute dose giving serum 
concentrations at  20  and 30 minutes corresponding to the upper limit of those observed 
in the serum of patients and healthy volunteers following treatment with well-tolerated 
doses of memantine (Parsons et al. 2007). 
All solutions were suited to physiological pH value and injected intraperitoneally (i.p.) 
at a volume of 1 ml/kg (300µL). All procedures were conducted in accordance with the 
NIH Guide for Care and Use of Laboratory Animals (NIH Publication N0. 85-23, 
revised 1996) and were approved by local Animal Care and Use Committee. All efforts 
were made to minimize the number of animals and their sufferance. 
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Tissue sectioning. 
After the killing, the brains were removed, frozen on dry ice and stored at −45 ◦C. 
Coronal sections of 12µm were cut on a cryostat -20°C, using the rat brain atlas by 
Paxinos and Watson (Paxinos and Watson, 1997) at the level of the middle-rostral 
striatum (approximately from Bregma -0.2 mm to -1.00 mm), of hippocampus (rostral 
regions of retrosplenial cortex; approximately from Bregma -3.00 mm to -4.50 mm), of 
substantia nigra/VTA (caudal regions of retrosplenial cortex- midbrain; approximately 
From -4.50 mm to -6.20 mm). Sections were thaw-mounted onto gelatine-coated slides; 
subsequently, they were processed for radioactive in situ hybridization.  
 
Radiolabeling and purification of oligonucleotide probes. 
The Hk1 probe was a specifically designed 48-base oligodeoxyribonucleotide 
complementary to bases 827-874 of the rat Hk1 mRNA.  
The GLUT3 probe was a 48-base oligodeoxyribonucleotide complementary to bases 
1511-1558 of the rat GLUT3 mRNA (GenBank Accession n. D13962).  
The D1R probe was a 32-base oligodeoxyribonucleotide complementary to bases 829-
861 of the rat D1R mRNA (GenBank Accession n. #434).  
The D2R probe was a 48-base oligodeoxyribonucleotide complementary to bases 7-28 
of the rat D2R mRNA (GenBank Accession n. #436).  
The DAT probe was a 48-base oligodeoxyribonucleotide complementary to bases 871-
918 of the rat DAT mRNA (GenBank Accession n. NM012694).  
The Homer1a probe was a 48-base oligodeoxyribonucleotide complementary to bases 
2527–2574 of the rat Homer1a mRNA (GenBank Accession n. U92079).  
The Homer1b probe was a 48-base oligodeoxyribonucleotide complementary to bases 
1306-1353 of the rat Homer1b mRNA (GenBank Accession n. AF093268).  
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The PSD95 probe was a 45-base oligodeoxyribonucleotide complementary to bases 
225-269 of the rat PSD95 mRNA (GenBank Accession n. M96853).  
The c-fos probe was a 48-base oligodeoxyribonucleotide complementary to bases 270-
319 of the rat c-fos mRNA (GenBank Accession n. NM022197.2).  
The Arc probe was a 45-base oligodeoxyribonucleotide complementary to bases 833-
878 of the rat Arc mRNA (GenBank Accession n. NM019361).  
The specificity of each probe was also tested by pilot control experiment using the 
corresponding sense oligodeoxyribonucleotide. All the oligodeoxyribonucleotides were 
purchased from MWG Biotech (Firenze, Italy). For each probe a 50 µl labeling reaction 
mix was prepared on ice using DEPC-treated water, 1X tailing buffer (metabolic 
paradigm) or 5X tailing buffer (PSD paradigm), 7.5pmol/μl (metabolic paradigm) or 5 
pmol/µl (PSD paradigm) of oligodeoxyribonucleotide, 125 units (metabolic paradigm)  
or 2,5 units (PSD paradigm) of terminal deoxynucleotidyl transferase (TdT) and 100 
mCi 35S-dATP. The mix was incubated 20 min at 37°C. The unincorporated 
nucleotides were separated from radiolabeled DNA using ProbeQuant G-50 Micro 
Columns (Amersham–GE Healthcare Biosciences; Milano, Italy).  
 
In situ hybridization procedures. 
Sections were processed for radioactive in situ hybridization (Ambesi-Impiombato et al. 
2003; Tomasetti et al. 2007; Dell'aversano et al. 2009). All solutions were prepared with 
sterile double-distilled water. The sections were fixed in 4% formaldehyde in 0.12 M 
phosphate-buffered saline (1X PBS, pH 7.4) for five minutes, quickly rinsed twice with 
1X PBS, and placed in 0.25% acetic anhydride in 0.1 M triethanolamine, 0.9% NaCl, 
pH 8.0, for 10 min at room temperature. Next, the sections were dehydrated in 70%, 
80%, 95% and 100% ethanol, delipidated in chloroform for 5 min, rinsed again in 100% 
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and 95% ethanol and air dried. Sections were hybridized with 0.4–0.6x106 c.p.m. of 
radiolabeled oligonucleotide in buffer containing 50% formamide, 600mM NaCl, 
80mM Tris–HCl (pH 7.5), 4mM EDTA, 0.1% pyrophosphate, 0.2% SDS, 0.2 mg/ml 
heparin sulfate, and 10% dextran sulphate, 100 mM DTT 5M. Slides were covered with 
coverslips and incubated at 37°C in a humid chamber for 22 h. After hybridization the 
coverslips were removed in 1X SSC (saline sodium citrate solution) and the sections 
were washed four times of 15 min in 2X SSC/50% formamide at 43–44 °C, followed by 
two 30 min washes with 1X SSC at room temperature. The slides were rapidly rinsed in 
distilled water and then in 70% ethanol. 
 
Image capture and statistical analysis.  
Hybridized sections were dried and exposed to Kodak-Biomax MR Autoradiographic 
film (Sigma-Aldrich). A slide containing a scale of 16 known amounts of 14C standards 
(American Radiolabeled Chemicals, St. Louis, MO, USA) was co-exposed with the 
samples. The autoradiographic films were exposed in a time range of 14–30 days. The 
optimal time of exposure was chosen to maximize signal-to-noise ratio but to prevent 
optical density from approaching the limits of saturation. Film development protocol 
included a 1.5 min dip in the developer solution, a 30 seconds rinse in water, a 3 min in 
the fixer and a 30 seconds rinse in water. 
 
Image analysis. 
The quantitation of the autoradiographic signal was performed using a computerized 
image analysis system including: a transparency film scanner (Microtek Europe B. V., 
Rotterdam, The Netherlands), an Apple PowerPC G4, and ImageJ software (v. 1.40, 
Rasband, W.S., http://rsb.info.nih.gov/ij/). Sections on film were captured individually. 
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The original characteristics of the scanned images (i.e. contrast, brightness, resolution) 
were preserved. All hybridized sections were exposed on the same sheet of X-ray film. 
Signal intensity analysis was carried out on digitized autoradiograms measuring mean 
optical density within outlined regions of interest (ROIs; Fig.1) in correspondence of 
subregions of the cortex (frontal, retrosplenial, enthorinal, visual, auditory cortices), 
caudate putamen, nucleus accumbens, ventro tegmental area, substantia nigra, midbrain. 
Sections were quantitated blind to the treatment conditions. In order to test for inter-
observer reliability an independent quantitation was performed by a second investigator. 
Results obtained by the first investigator were considered reliable, and then reported, 
only when they were quantitatively comparable, in terms of consistency of the 
statistically significant effects found, to that obtained by the second investigator. 
 
Data processing. 
Measurements of mean optical density within ROIs were converted using a calibration 
curve based on the standard scale co-exposed to the sections. 14C standard values from 
4 through 12 were previously cross-calibrated to 35S brain paste standards, in order to 
assign a d.p.m./mg tissue wet weight value to each optical density measurement through 
a calibration curve. For this purpose a “best fit” 3rd degree polynomial was used. For 
each animal, measurements from the three adjacent sections were averaged and the final 
data were reported in relative d.p.m. as mean +/- S.E.M. A One-Way Analysis of 
Variance (ANOVA) was used to analyze treatment effects. The Student’s t test and the 
Student-Newman-Keuls post hoc test was used to determine the locus of effects in any 
significant ANOVA.  
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Figure 1. Region of Interests (ROIs) 
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Chapter 3. 
Modulation of Hk1 and GLUT3 in an animal model of psychosis: a putative link 
between metabolism and behavioral disorders. 
 
Rationale. 
Schizophrenia has long been associated to an impairment of glucose regulation. Co-
occurrence of schizophrenia and type 2 diabetes mellitus has been described (Bellivier 
2005), which may be due to common genetic and environmental factors. Given their 
involvement in both glucose metabolism and cognitive functions, a cluster of putative 
genes for both schizophrenia and type 2 diabetes mellitus, including glycogen synthase 
kinase 3 (GSK-3), tyrosine hydroxylase (TH) and dopamine D2 receptor  (D2R), is 
currently under investigation (Lin and Shuldiner 2010).  
Molecules involved in intracellular glucose metabolism may also be implicated in 
psychosis or in the mechanism of action and side effects of antipsychotics (Beaulieu et 
al. 2004; Beaulieu et al. 2005; Chen et al. 2007). Among key genes of glucose 
metabolism that have been associated with psychosis are Hexokinase1 and Glucose 
Transporter type 3. 
Hexokinases (Hk, ATP:D-esose 6-phosphotransferase) catalyze the phosphorylation of 
glucose to glucose-6-phosphate (G6P), the first and limiting reaction in glucose 
metabolism necessary for intake of glucose through glucose transporters and for 
subsequent glycolysis and glycogen synthesis (Yano et al. 1991; Roncero et al. 2000; 
Wilson 2003).  
Hk 1,2,3 isoenzymes are about 100 KDa, have high affinity for glucose and are 
regulated by feedback by G6P; Hk4 isoenzyme is about 52KDa, exhibits lower glucose 
affinity and is not regulated by feedback (Roncero et al. 2000). Hk isoforms have 
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substantial conservation of amino acid sequences and may be differentiated according to 
biochemical and pharmacological features, including tissue distribution: Hk1 shows 
ubiquitous tissue distribution. High levels of Hk1 mRNA expression and 
immunoreactivity have been demonstrated within brain tissues (Jacobsson and Meister 
1994; Coerver et al. 1998)). Hk2 is distributed in insulin-sensible tissues, such as 
muscle and adipocyte; Hk4 is distributed in hepatocytes and in pancreatic islands 
(Cardenas et al. 1998).  
Hk1 and Hk2 are saturated by normal blood glucose concentration and are even 
activated when glucose concentration is lower than the physiologic range, in order to 
preserve the brain metabolism.  
Hk3 activity is inhibited by high levels of blood glucose. Hk4 activity depends on 
variation of glucose concentration within the blood range (Cardenas et al. 1998). 
Within the subcellular fraction, Hk1 is localized at the outer portion of mitochondria 
membrane (Polakis and Wilson 1985; Xie and Wilson 1988; Sui and Wilson 1997; 
Wilson 2003; Golestani et al. 2007) and acts in neurons also as an anti-apoptotic agent 
via its interaction with the voltage-dependent anion channel-1 (VDAC-1) protein 
(Pastorino and Hoek 2003; Wilson 2003; Pastorino and Hoek 2008). Intriguingly, the 
Hk1 interaction with mitochondria, which is required to prevent apoptosis, is mediated 
by the serine-threonine kinase Akt (Martins-De-Souza et al. 2010) and by GSK3b 
(glycogen- synthase- kinase) that have been implicated in pathophysiology of psychosis 
and in response to antipsychotics (Emamian et al. 2004; Lang et al. 2007; Pastorino and 
Hoek 2008). The Hk gene has been found in linkage with schizophrenia susceptibility 
regions of the genome (Stone et al. 2004).  
The glucose transporters' family is composed by co-transporter Sodium-Glucose and 
Glucose Transporter (GLUT). GLUTs are involved in a passive mechanism of 
 31 
facilitated glucose diffusion. Among all GLUT isoforms, GLUT1 (high molecular 
weight isoform) is expressed by capillary of blood-brain barrier, GLUT2 (low 
molecular weight isoform) in glial cells, and GLUT3 in neurons (Leino et al. 1997; 
Vannucci et al. 1997; McEwen and Reagan 2004; Simpson et al. 2007). 
GLUT3 is the most abundant in the brain, while its expression is limited in other tissues 
such as sperm, embryo, leucocyte, tumor cells (Maher et al. 1991; McCall et al. 1994; 
Leino et al. 1997; Vannucci et al. 1997). GLUT3 expression increases during 
synaptogenesis and during neuronal activity. GLUT3 has high affinity for glucose 
(Palfreyman et al. 1992; Nishimura et al. 1993; Maher et al. 1996). A deficit in 
membrane-bound glucose transporter proteins, as GLUT1 and GLUT3, has recently 
been proposed as a putative mechanism in Alzheimer disease and in schizophrenia 
(Simpson et al. 1994; Miyamoto et al. 2001; Simpson et al. 2008). Moreover, 
antipsychotics have been reported to impair glucose uptake and increase GLUT3 
expression, after long term exposure, in cultured cells (Dwyer et al. 1999). 
This body of evidence let suppose that Hk1 and GLUT3 may be implicated in neuro-
psychiatric diseases, as psychosis. In this study, we aimed to evaluate the expression of 
Hk1 and GLUT3 in rat brain areas relevant for schizophrenia pathophysiology and 
therapy after exposure to ketamine, a compound known to induce a state of NMDA-R 
hypofunction which may represent an animal model of psychosis.   
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Results. 
Expression of Hk1 and GLUT3 genes has been investigated in rat brain regions of 
interest considered relevant for ketamine-induced psychosis in humans and/or for 
ketamine-mediated neurotoxicity in rats, that is believed to model psychosis 
mechanisms (Table 1-2; Fig.2-3-4-5).  
 
Frontal cortex. 
Hk1 mRNA expression was not significant different among groups, with the exception 
of the somatosensory cortex where KET50 significantly increased Hk1 mRNA 
expression compared to VEH.  
GLUT3 gene expression was significantly increased by KET12 compared to both 
KET50 and VEH in the somatosensory and insular cortices and compared to KET50 
only in the anterior cingulate, medial agranular, and motor cortices. 
 
Retrosplenial cortex. 
Hk1 expression was significantly increased by KET50 compared to VEH and KET12 in 
granular and dysgranular caudal cortices and by KET50 compared to VEH in granular 
rostral cortex, while no significant differences were detected in agranular rostral cortex. 
GLUT3 gene expression was not significantly affected by ketamine. 
 
Enthorinal cortex.  
Both Hk1 and GLUT3 gene expression was not significantly affected by ketamine in 
this region. 
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Auditory cortex. 
Quantization carried out in the caudal sections showed that Hk1 gene expression was 
significantly increased by KET50 compared to both KET12 and VEH in the primary 
auditory cortex and in the ventral area of the secondary auditory cortex, while no 
significant differences among groups were observed in the dorsal area of the secondary 
auditory cortex. In the ventral area of the secondary auditory cortex, KET12 
significantly reduced Hk1 expression when compared to vehicle.  
No significant differences among groups as related to GLUT3 expression were found in 
any of the auditory cortex subregion.  
In the rostral sections, Hk1 expression was significantly increased by both KET50 and 
KET12 compared to vehicle in all auditory cortex subregions. No significant differences 
between KET50 and KET12 were recognized.  
GLUT3 expression was found unaffected by treatments in rostral sections of auditory 
cortex.  
 
Visual cortex. 
In primary and secondary (either mediomedial, mediolateral, or lateral) visual cortices, 
Hk1 expression was found to be significantly increased by KET50 compared to both 
KET12 and vehicle. 
GLUT3 expression was found to be not affected by treatments in these regions.  
 
Striatum.  
Expression of Hk1 gene was significantly increased by KET50 compared to both 
KET12 and VEH in the dorsomedial, dorsolateral, and ventromedial caudate putamen 
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and in the core of nucleus accumbens. No significant differences were recognized in the 
ventrolateral caudate putamen and in the shell of the nucleus accumbens.  
GLUT3 expression was significantly decreased by KET50 compared to both KET12 and 
VEH in dorsomedial, dorsolateral, and ventromedial caudate putamen; and compared to 
KET12 only in ventrolateral caudate putamen and in the shell of the nucleus accumbens. 
In the core of the nucleus accumbens, KET50 also reduced GLUT3 expression 
compared to KET12, albeit only a trend toward significance (ANOVA, p=0.057) was 
found. 
 
Lateral Septum.  
Hk1 expression was not significantly affected by treatments in any of the lateral septum 
subregions.  
GLUT3 expression was significantly decreased by KET50 compared to both KET12 and 
vehicle in the dorsal part of the lateral septum and compared to the KET12 only in the 
intermediate part of the lateral septum. No significant differences were recognized in 
the ventral part.   
 
Substantia Nigra and Ventrotegmental area. 
Hk1 expression resulted to be not significantly affected by treatments in both the 
ventrotegmental area and the substantia nigra (either pars reticulata or pars compacta), 
although a trend toward significance was observed in the substantia nigra pars reticulata 
(i.e.: Hk1 expression increased by KET50 compared to KET12 and vehicle).  
No significant differences among groups in GLUT3 expression were found in these 
regions. 
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 KET50 KET12 VEH 
ANOVA 
(df, p) 
Frontal cortex     
Anterior Cingulate cortex 93.571.04 91.091.49 89.211.72 
F2,8=2.33 
P=0.159 
Medial Agranular Cortex 91.341.77 87.592.42 86.572.38 
F2,8=1.31 
P=0.326 
Motor Cortex 93.351.09 89.721.58 89.241.71 
F2,8=2.43 
P=0.149 
Somatosensory Cortex 90.430.96* 88.961.26* 84.591.37 
F2,8=5.88 
P=0.027 
Insular Cortex 94.781.11 94.011.51 85.627.01 
F2,8=2.01 
P=0.197 
 
Retrosplenial Cortex     
Rostral Granular Cortex 151.468.64* 126.813.55 117.1627.17 
F2,7=6.35 
P=0.026 
Rostral Dysgranular Cortex 151.829.46 142.045.13 122.148.39 
F2,7=3.68 
P=0.08 
Caudal Granular Cortex 144.457.71** 109.132.83 122.396.56 
F2,8=8.86 
P=0.009 
Caudal Dysgranular Cortex 160.016.72** 119.815.88 129.237.67 
F2,8=8.41 
P=0.01 
 
Enthorinal Cortex 89.673.25 83.451.14 85.371.49 
F2,7=2.53 
P=0.15 
 
Rostral Auditory Cortex     
Primary Auditory Cortex 92.661.09* 92.951.25* 86.462.23 
F2,8=5.59 
P=0.0303 
Dorsal Secondary Auditory 
Cortex 
92.091.41* 91.491.42* 83.861.27 
F2,8=9.49 
P=0.007 
Ventral Secondary Auditory 
Cortex  
94.221.08* 93.151.73* 87.880.89 
F2,8=5.53 
P=0.031 
Caudal Auditory Cortex     
Primary Auditory Cortex 93.810.14** 88.511.37 89.271.13 
F2,7=6.11 
P=0.029 
Dorsal Secondary Auditory 
Cortex 
91.830.66 87.632.88 85.862.18 
F2,7=1.53 
P=0.28 
Ventral Secondary Auditory 
Cortex 
93.980.26** 87.760.88# 91.250.45 
F2,7=21.69 
P=0.001 
 
Visual Cortex     
Primary Visual Cortex 91.650.44** 86.371.13 84.651.36 
F2,7=10.33 
P=0.008 
Mediomedial Secondary 
Visual Cortex 
91.710.35** 86.871.33 86.370.51 
F2,7=7.99 
P=0.015 
Mediolateral Secondary 
Visual Cortex 
91.910.51** 86.870.48 85.630.73 
F2,7=31.16 
P=0.0003 
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Table 1. mRNA levels of Hexokinase I after acute ketamine treatment. Data are 
expressed as d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain 
regions analyzed, along with the relative ANOVA (degrees of freedom and p values). 
Significant p values are expressed in bold. Post-hoc test: ** significantly higher 
expression compared to KET12 and VEH; * significantly higher expression compared 
to VEH; # significantly lower expression compared to VEH.   
 
Lateral Secondary Visual 
Cortex 
91.320.42** 87.260.84 84.441.81 
F2,7=8.65 
P=0.013 
 
Striatum     
Dorsomedial Caudate 
Putamen 
74.891.34** 68.081.15 69.541.19 
F2,8= 8.74 
P=0.0097 
Dorsolateral Caudate 
Putamen 
73.971.23** 68.371.85 66.790.78 
F2,8=6.63 
P=0.02 
Ventromedial Caudate 
Putamen 
75.030.91** 70.291.88 68.871.16 
F2,8=5.03 
P=0.038 
Vetrolateral Caudate 
Putamen 
74.281.39 70.232.58 66.491.14 
F2,8=3.79 
P=0.06 
Core of the Nucleus 
Accumbens 
80.750.65** 72.181.96 73.280.47 
F2,8=12.87 
P=0.003 
Shell of the Nucleus 
Accumbens 
81.180.98 75.493.31 75.810.71 
F2,8=2.16 
P=0.18 
 
Lateral Septum     
Dorsal Lateral Septal 
Nucleus 
81.581.37 79.152.41 75.131.31 
F2,7=2.47 
P=0.15 
Intermediate Lateral Septal 
Nucleus 
83.281.05 78.532.47 76.192.59 
F2,7=2.29 
P=0.17 
Ventral Lateral Septal 
Nucleus 
84.751.97 79.982.29 77.613.76 
F2,7=1.63 
p=0.26 
 
Substantia 
Nigra/Ventrotegmental Area 
    
Substantia Nigra Pars 
Compacta 
85.153.24 79.640.71 80.012.32 
F2,7=2.08 
P=0.19 
Substantia Nigra Pars 
Reticulata 
64.870.74** 52.494.12 49.794.28 
F2,7=4.39 
P=0.05 
Ventrotegmental Area 88.641.59 84.992.96 81.070.26 
F2,7=2.49 
P=0.15 
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 KET50 KET12 VEH 
ANOVA 
(df, p) 
Frontal cortex     
Anterior Cingulate cortex 72.991.08 83.382.61◊ 79.882.19 
F2,8=5.14 
P=0.036 
Medial Agranular Cortex 68.813.18 81.170.96◊ 75.392.03 
F2,8=8.66 
P=0.01 
Motor Cortex 66.764.24 80.591.98◊ 76.112.76 
F2,8=5.41 
P=0.032 
Somatosensory Cortex 62.033.98# 80.682.04** 72.552.04 
F2,8=12.25 
P=0.003 
Insular Cortex 72.466.46 90.272.99** 76.341.79 
F2,8=6.49 
P=0.021 
 
Retrosplenial Cortex     
Rostral Granular Cortex 61.965.95 80.2310.11 57.575.45 
F2,8=2.58 
P=0.13 
Rostral Dysgranular Cortex 61.884.79 82.0411.85 59.085.02 
F2,8=2.53 
P=0.13 
Caudal Granular Cortex 61.833.42 67.908.54 62.349.70 
F2,7=0.16 
P=0.85 
Caudal Dysgranular Cortex 63.802.25 67.597.15 62.069.27 
F2,7=0.15 
P=0.86 
 
Enthorinal Cortex 70.626.14 84.440.88 73.865.71 
F2,7=2.21 
P=0.19 
 
Rostral Auditory Cortex     
Primary Auditory Cortex 73.650.78 82.011.35 66.616.81 
F2,7=3.64 
P=0.09 
Dorsal Secondary Auditory 
Cortex 
72.091.07 80.912.34 64.136.79 
F2,7=3.99 
P=0.07 
Ventral Secondary Auditory 
Cortex  
75.730.73 84.080.32 71.915.98 
F2,7=3.19 
P=0.11 
Caudal Auditory Cortex     
Primary Auditory Cortex 80.932.97 86.712.08 75.147.22 
F2,7=1.53 
P=0.28 
Dorsal Secondary Auditory 
Cortex 
76.153.01 82.691.82 69.355.91 
F2,7=2.82 
P=0.13 
Ventral Secondary Auditory 
Cortex 
81.542.85 88.633.35 75.358.21 
F2,7=1.53 
P=0.29 
 
Visual Cortex     
Primary Visual Cortex 75.721.29 83.782.63 68.768.43 
F2,7=2.13 
P=0.2 
Mediomedial Secondary Visual 
Cortex 
74.653.22 84.462.24 71.347.91 
F2,7=1.79 
P=0.24 
Mediolateral Secondary Visual 
Cortex 
73.372.12 85.152.37 70.587.09 
F2,7=2.97 
P=0.12 
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Table 2. mRNA levels of Glucose Transporter 3 after acute ketamine treatment. 
Data are expressed as d.p.m. mean valuesstandard error means (S.E.M.) and listed by 
brain regions analyzed, along with the relative ANOVA (degrees of freedom and p 
values). Significant p values are expressed in bold. Post-hoc test: ** significantly higher 
expression compared to KET50 and VEH; 
◊
 significantly higher expression compared 
to KET50; # significantly lower expression compared to VEH. 
 
Lateral Secondary Visual Cortex 74.132.67 82.981.45 70.228.58 
F2,7=1.55 
P=0.28 
 
Striatum     
Dorsomedial Caudate Putamen 50.241.35# 68.523.61◊ 62.371.75 
F2,8= 11.34 
P=0.0046 
Dorsolateral Caudate Putamen 47.970.93# 63.572.41◊ 58.211.29 
F2,8=17.77 
P=0.0011 
Ventromedial Caudate Putamen 46.561.83# 65.613.68◊ 59.992.13 
F2,8=10.77 
P=0.0054 
Vetrolateral Caudate Putamen 45.110.71 64.984.25◊ 54.953.06 
F2,8=8.21 
P=0.011 
Core of the Nucleus Accumbens 50.021.34 64.364.16◊ 60.023.26 
F2,8=4.17 
P=0.05 
Shell of the Nucleus Accumbens 52.963.33 71.633.68◊ 63.323.34 
F2,8=6.58 
P=0.021 
 
Lateral Septum     
Dorsal Lateral Septal Nucleus 48.391.31# 64.594.38◊ 58.771.69 
F2,7=10.87 
P=0.007 
Intermediate Lateral Septal 
Nucleus 
46.783.76 63.414.41◊ 58.613.45 
F2,7=5.09 
P=0.04 
Ventral Lateral Septal Nucleus 55.972.61 67.534.76 63.452.88 
F2,7=3.17 
p=0.11 
 
Substantia 
Nigra/Ventrotegmental Area 
    
Substantia Nigra Pars Compacta 71.512.88 76.019.69 63.895.69 
F2,7=0.83 
P=0.48 
Substantia Nigra Pars Reticulata 42.021.92 53.589.95 42.959.08 
F2,7=0.66 
P=0.54 
Ventrotegmental Area 68.441.21 75.196.88 55.986.83 
F2,7=2.99 
P=0.12 
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Figure 2. Autoradiographic images and graphics of Hk1 mRNA expression in relative dpm as 
mean ± S.E.M.; *ANOVA p<0,05 vs VEH. 
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Figure 3. Autoradiographic images and graphics of Hk1 mRNA expression in relative dpm as 
mean ± S.E.M.; *ANOVA p<0,05 vs VEH. 
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Figure 4. Autoradiographic images and graphics of GLUT3 mRNA expression in relative 
dpm as mean ± S.E.M.; *ANOVA p<0,05 vs VEH. 
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Figure 5. Autoradiographic images and graphics of GLUT3 mRNA expression in relative 
dpm as mean ± S.E.M.; *ANOVA p<0,05 vs VEH. 
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Chapter 4. 
Modulation of Dopamine Receptors type 1-2 and Dopamine Transporter in an 
animal model of psychosis: acute and subchronic paradigms. 
 
Rationale 
The imbalance between dopaminergic and glutamatergic neurotransmission at both 
cortical and subcortical level is regarded as one of the main pathophysiological 
mechanisms of psychosis (de Bartolomeis et al. 2005).   
Moving from early suggestions that only implicated dopamine dysfunctions in psychosis,  
in recent years, e the glutamatergic hypothesis of psychosis pathophysiology has 
received even greater attention  (Allen and Young 1978; Lodge and Anis 1982; Javitt 
and Zukin 1991). According to this hypothesis, a failure in glutamatergic 
neurotransmission, namely a NMDA-R hypofunction, may cause a complex cortical-
subcortical perturbation involving several neurotransmitter systems, including the 
dopaminergic (Olney et al. 1999; Farber 2003). Consistent with glutamatergic hypothesis 
of psychosis, animal models provided by acute or subchronic administration of NMDA-
Rs non-competitive antagonists, as ketamine, are considered to have strong predictive 
and construct validity (Lipska and Weinberger 2000). Thereby, these pharmacological 
models represent a powerful tool to study novel therapeutic targets  and molecular basis 
of psychotic disorders and have allowed to carry out  investigations on the dopamine-
glutamate interplay in psychosis-mimicking paradigms.  
Blockade of NMDA-R, by systemic NMDA-R blockers administration, has been 
reported to increase dopamine release in the cortex and ventral striatum in rats (Ikeda et 
al. 2011) and at least in striatum in humans (Kegeles et al. 2002). Chronic recreational 
users of ketamine have been demonstrated to suffer from a reduction of dopamine D1R 
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amount in the cortex (Narendran et al. 2005). Exposure to phencyclidine (PCP), a potent 
NMDA-R non-competitive antagonist, in rat puppets has been shown to decrease 
dopamine D2R binding in the striatum along different time points, as well as to slightly 
increase dopamine transporter (DAT) binding and tyrosine hydroxylase mRNA 
expression, suggesting a long-term increase of dopamine output. Moreover, it has been 
observed that antipsychotics, which are known to mainly act on dopamine 
neurotransmission, reverse the disruption in rat prefrontal cortex functions triggered by 
blockade of NMDA-Rs (Kargieman et al. 2007). It thus appears that dysfunctions in 
glutamate transmission may be associated to the perturbation of dopamine signaling and 
dopamine-mediated behaviors, which may be of relevance for psychosis 
pathophysiology. However, molecular mechanisms of glutamate-dopamine interplay in 
animal models of psychosis are yet to be exhaustively described.  Moreover, some 
controversy is still under debate on whether psychosis may be best resembled after acute 
or subchronic administration of NMDA-R non-competitive antagonists. It is believed 
that acute administration of these compounds may induce neurochemical and behavioral 
manifestations consistent with acute positive and negative symptoms of psychosis 
(Gunduz-Bruce 2009). On the other hand, chronic exposure to NMDA-R non-
competitive antagonists has been described to induce cortical dopaminergic and 
cognitive deficits in rats and monkeys, providing a model of  cortical dysfunctions in 
psychosis (Jentsch et al. 1998). Moreover, subchronic PCP has been reported to induce 
hyperreactivity of striatal dopamine release and dopamine sensitization to 
psychostimulants (Jentsch et al. 1998; Balla et al. 2001), which may model the putative 
sustained perturbation of dopamine transmission occurring in schizophrenic individuals. 
In this study, our first goal was to verify whether perturbation of NMDA-R-mediated 
transmission may reflect in the perturbation of dopamine neurotransmission. To do so, 
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we investigated changes in gene expression in key molecules regulating dopamine 
signaling, namely the gene coding for dopamine D1 and D2Rs and for the DAT. As a 
second goal, we wanted to evaluate whether putative changes may be specific of one 
paradigm of ketamine administration (acute or  subchronic, respectively) and whether 
putative changes were preserved or vary with the period of ketamine administration.  
Dopamine receptors are a family of metabotropic G-protein coupled receptors. There are 
at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 
receptors are members of the D1-like family of dopamine receptors; activation of D1-
like family receptors is coupled to the G protein Gαs, which subsequently activates 
adenylyl cyclase, increasing the intracellular concentration of the second messenger 
cyclic adenosine monophosphate (cAMP), and activates cyclic AMP-dependent protein 
kinases. The D2, D3 and D4 receptors are members of the D2-like family; activation of 
D2-like family receptors is coupled to the G protein Gαi, which directly inhibits the 
adenylate cyclase decreasing the intracellular concentration of cAMP (Girault and 
Greengard 2004). 
D1R is the most expressed dopamine receptors in the neocortex. D1R is a postsynaptic 
receptor of neurons involved in the meso-cortical pathway from the ventral tegmental 
area to the neocortex (Lewis and Howie 1987). Altered D1R function in dorso-lateral 
prefrontal cortex has been involved in the working memory impairment in schizophrenia 
(Weinberger 1987; Davis et al. 1991; Goldman-Rakic et al. 2000; Abi-Dargham et al. 
2002). 
D2R is encoded in two forms: the D2L form is a post-synaptic receptor, with both 
excitatory or inhibitory transmission functions; the D2S form is a presynaptic 
autoreceptor with modulatory functions by feed-back mechanisms, affecting synthesis, 
storage, and release of dopamine into the synaptic cleft. Low doses of an agonist prefer 
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the presynaptic and high doses prefer the postsynaptic D2Rs. When the dopamine in the 
synapse binds the presynaptic D2R, the presynaptic neuron is inhibited. Virtually all 
antipsychotic agents  are antagonists at the D2R, except for aripiprazole that works as 
D2R partial agonist. D2R antagonism is functional to control positive symptoms of  
schizophrenia.  
DAT is a pre-synaptic transporter involved in the clearance of dopamine in striatum 
regions. The rate at which DAT removes dopamine from the synapse can have effects on 
the amount of dopamine in the neuron. Dysfunction of DAT activity is involved in 
severe cognitive deficits and motor abnormalities. 
In this study, we aimed to evaluate the expression of D1R, D2R and DAT in rat brain 
areas relevant for schizophrenia pathophysiology and therapy after perturbation of 
glutamate system in an acute and a subchronic paradigms. 
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Results. 
D1R- Acute paradigm 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test, 
graphics and autoradiographic images are shown in Fig.6.  
A significant reduction of D1R gene expression was observed in the dorsolateral caudate 
putamen (DLCP, ANOVA, p=0.0473; F(2,8)=4.5791) and in the ventrolateral caudate 
putamen (VLCP, ANOVA, p=0.0253; F(2,8)=6.0282), following the treatment with 
ketamine 50 mg/kg and ketamine 12 mg/kg as compared to the vehicle.  
A significant reduction of D1R gene expression was observed in the core of nucleus 
accumbens (Core, ANOVA, p=0.0474; F(2,8)=4.5739) following the treatment with 
ketamine as compared to the vehicle. 
No significant changes in D1R expression were detected in anterior cingulate cortex 
(AC, ANOVA, p=0.1945; F(2,8)=2.0232), premotor cortex (M2, ANOVA, p=0.2749; 
2,8=1.5240); motor cortex (M1, ANOVA, p=0.1067; F(2,8)=2.9984); somatosensory 
cortex (SS, ANOVA, p=0.0750; F(2,8)=3.6440); insular region (I, ANOVA, p=0.0819; 
F(2,8)=3.4763); dorsomedial caudate putamen (DMCP, ANOVA, p=0.1008; 
F(2,8)=3.0987); ventromedial caudate putamen (VMCP, ANOVA, p=0.0690; 
F(2,8)=3.8057); shell of accumbens (Shell, ANOVA, p=0.0856; F(2,8)=3.3953) 
following the treatment with ketamine 50 mg/kg or ketamine 12 mg/kg as compared to 
the vehicle.  
 
D2R- Acute paradigm 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test, 
autoradiographic images and graphics are shown in Fig.7-8.  
 50 
No significant induction of D2R gene expression was observed in cortical subregions: in 
anterior cingulate cortex (AC, ANOVA, p=0.3874; F(2,8)=1.0700), premotor cortex 
(M2, ANOVA, p=0.0777; F(2,8)=3.5751); motor cortex (M1, ANOVA, p=0.3503; 
F(2,8)=1.1995); somatosensory cortex (SS, ANOVA, p=0.7187; F(2,8)=0.3443), insular 
region (I, ANOVA, p=0.4035; F(2,8)=1.0189) following the treatment with ketamine 50 
mg/kg, ketamine 12 mg/kg as compared to the vehicle.  
No significant induction of D2R gene expression was observed in striatum subregions: in 
dorsolateral caudate putamen (DLCP, ANOVA, p=0.3784; F(2,8)=1.0999), in 
ventrolateral caudate putamen (VLCP, ANOVA, p=0.2781; F(2,8)=1.5083); in 
dorsomedial caudate putamen (DMCP, ANOVA, p=0.2250; F(2,8)=1.8079); in 
ventromedial caudate putamen (VMCP, ANOVA, p=0.2288; F(2,8)=1.7837); following 
the treatment with ketamine 50 mg/kg or ketamine 12 mg/kg as compared to the vehicle.  
No significant changes in D2R expression were detected in core of nucleus accumbens 
(Core, ANOVA, p=0.0888; F(2,8)=3.3269) and shell of accumbens (Shell, ANOVA, 
p=0.6072; F(2,8)=0.5314) following the treatment with ketamine 50 mg/kg or ketamine 
12 mg/kg as compared to the vehicle. 
No significant changes in D2R expression were detected in ventrotegmental Area (VTA, 
ANOVA, p=0.7017; F(2,8)=0.3703); substantia nigra pars compacta (SNpc, ANOVA, 
p=0.9862; F(2,8)=0.0139); substantia nigra pars reticulata (SNpr, ANOVA, p=0.7898; 
F(2,8)=0.2431) following the treatment with ketamine 50 mg/kg or ketamine 12 mg/kg 
as compared to the vehicle. 
 
D1R- Subchronic paradigm 
Results, with respective ANOVA values and Student’s T test; graphics and 
autoradiographic images are shown in Fig.9.  
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No significant induction of D1R gene expression was observed in cortical subregions: in 
anterior cingulate cortex (AC, ANOVA, p=0.8260; F(2,4)=0.0528), premotor cortex 
(M2, ANOVA, p=0.5411; F(2,4)=0.4197); motor cortex (M1, ANOVA, p=0.8625; 
F(2,4)=0.0327); somatosensory cortex (SS, ANOVA, p=0.7528; F(2,4)=0.1087); insular 
region (I, ANOVA, p=0.7882; F(2,4)=0.0789) following the treatment with ketamine 12 
mg/kg as compared to the vehicle.  
No significant induction of D1R gene expression was observed in striatum subregions: in 
dorsolateral caudate putamen (DLCP, ANOVA, p=0.8555; F(2,4)=0.0362); ventrolateral 
caudate putamen (VLCP, ANOVA, p=0.7559; F(2,4)=0.1059); dorsomedial caudate 
putamen (DMCP, ANOVA, p=0.5117; F(2,4)=0.4862); ventromedial caudate putamen 
(VMCP, ANOVA, p=0.5594; F(2,4)=0.3818) following the treatment with ketamine 12 
mg/kg as compared to the vehicle.  
No significant changes in D1R expression were detected in core of nucleus accumbens 
(Core, ANOVA, p=0.6844; F(2,4)=0.1821) and shell of accumbens (Shell, ANOVA, 
p=0.8791; F(2,4)=0.0252) following the treatment with ketamine 12 mg/kg as compared 
to the vehicle. 
 
D2R- Subchronic paradigm 
Results, with respective ANOVA values and Student’s t test, graphics and 
autoradiographic images are shown in Fig.10-11. A significant induction of D2R gene 
expression was observed in ventrotegmental area (VTA, ANOVA, p<0.0001; 
F(2,4)=133.9264) following the treatment with ketamine 12 mg/kg as compared to the 
vehicle. A significant induction of D2R gene expression was observed in retrosplenial 
dysgranular cortex (RSCd, ANOVA, p=0.0071; F(2,4)=16.0560) following the 
treatment with ketamine 12 mg/kg as compared to the vehicle. 
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No significant induction of D2R gene expression was observed in cortical subregions: in 
anterior cingulate cortex (AC, ANOVA, p=0.9909; F(2,4)=0.0001), premotor cortex 
(M2, ANOVA, p=0.7094; F(2,4)=0.1527); motor cortex (M1, ANOVA, p=0.6526; 
F(2,4)=0.2242); somatosensory cortex (SS, ANOVA, p=0.7687; F(2,4)=0.0947), insular 
region (I, ANOVA, p=0.9988; F(2,4)=0) following the treatment with ketamine 12 
mg/kg as compared to the vehicle. No significant induction of D2R gene expression was 
observed in striatum subregions: dorsolateral caudate putamen (DLCP, ANOVA, 
p=0.7807; F(2,4)=0.0848); ventrolateral caudate putamen (VLCP, ANOVA, p=0.9882; 
F(2,4)=0.0002); dorsomedial caudate putamen (DMCP, ANOVA, p=0.9260; 
F(2,4)=0.0094); ventromedial caudate putamen (VMCP, ANOVA, p=0.9452; 
F(2,4)=0.0051) following the treatment with ketamine 12 mg/kg as compared to the 
vehicle. No significant changes in D2R expression were detected in core of nucleus 
accumbens (Core, ANOVA, p=0.9885; F(2,4)=0.0002) and shell of accumbens (Shell, 
ANOVA, p=0.5705; F(2,4)=0.3599) following the treatment with ketamine 12 mg/kg as 
compared to the vehicle. No significant changes in D2R expression were detected in 
substantia nigra pars compacta (SNpc, ANOVA, p=0.2462; F(2,4)=1.6512); substantia 
nigra pars reticulate (SNpr, ANOVA, p=0.1826; F(2,4)=2.2704); retrosplenial granular 
cortex (RSCg, ANOVA, p=0.0531; F(2,4)=5.7762) following the treatment with 
ketamine 12 mg/kg as compared to the vehicle. 
 
DAT- Subchronic paradigm 
Results, with respective ANOVA values and Student’s t test; graphics and 
autoradiographic images are shown in Fig.12. A significant induction of DAT gene 
expression was observed in substantia nigra pars compacta (SNpc, ANOVA, p=0.0189; 
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F(2,4)=10.1490); ventrotegmental area (VTA, ANOVA, p=0.0419; F(2,4)=6.6401) 
following the treatment with ketamine 12 mg/kg as compared to the vehicle.  
A significant reduction of DAT gene expression was observed in retrosplenial granular 
cortex (RSCg, ANOVA, p=0.0231; F(2,4)=10.4565); retrosplenial dysgranular cortex 
(RSCd, ANOVA, p=0.0081; F(2,4)=18.0824) following the treatment with ketamine 12 
mg/kg as compared to the vehicle. 
No significant changes in DAT expression were detected in substantia nigra pars 
reticulata (SNpr, ANOVA, p=0.3485; F(2,4)=1.0340); following the treatment with 
ketamine 12 mg/kg as compared to the vehicle. 
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Figure 6. Autoradiographic image and graphic of D1R mRNA expression in Frontal Cortex, 
Caudate Putamen and Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Figure 7. Autoradiographic image and graphic of D2R mRNA expression in Substatia Nigra 
and Ventrotegmental Area expressed in relative dpm as mean ± S.E.M.; *ANOVA p<0,05 vs 
VEH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ket12 Ket50 Veh 
 56 
 
 
 
 
 
 
 
 
 
 
 
D2R mRNA in Frontal Cortex
0
10
20
30
40
AC M2 M1 SS I
r
e
l 
d
p
m
KET 12
KET 50
VEH
 
D2R  mRNA in caudate-putamen and in 
nucleus accumbens
0
20
40
60
80
100
120
140
160
180
DLCP DMCP VMCP VLCP Core Shell
r
e
l 
d
p
m
KET 12
KET 50
VEH
 
 
 
Figure 8. Autoradiographic images and graphic of D2R mRNA expression in Frontal Cortex, 
Caudate Putamen and Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Figure 9. Autoradiographic images and graphic of D1R mRNA expression in Frontal Cortex, 
Caudate Putamen and Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Figure 10. Autoradiographic image and graphic of D2R mRNA expression in Frontal Cortex, 
Caudate Putamen and in Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
 
Ket12 Veh 
 59 
 
 
 
D2R mRNA in Substantia 
Nigra,VentroTegmental Area and
Retrosplenial Cortex
0
20
40
60
80
100
120
SNpr SNpc VTA RSCgranular RSCdysgranular
r
e
l 
d
p
m
VEH
KET 12
*
*
 
 
 
 
 
 
Figure 11. Autoradiographic image and graphic of D2R mRNA expression in Substantia 
Nigra, Ventrotegmental Area expressed in relative dpm as mean ± S.E.M.; *ANOVA p<0,05 
vs VEH. 
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Figure 12. Autoradiographic image and graphic of DAT mRNA expression in Substantia 
Nigra, Ventrotegmental Area and Retrosplenial Cortex expressed in relative dpm as mean ± 
S.E.M.; *ANOVA p<0,05 vs VEH. 
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Chapter 5. 
Modulation of constitutive and inducible early genes implicated in glutamate 
neurotransmission by different antagonists at NMDA receptors.  
 
Rationale. 
Dysfunctions in glutamatergic neurotransmission have been considered one of the main 
mechanisms in the pathophysiology of psychosis. Administration of non-competitive 
blockers of NMDA-R (i.e.: PCP, ketamine, and MK-801) has been observed to 
exacerbate psychotic symptoms in schizophrenic individuals and to trigger an exogenous 
psychosis in healthy volunteers recalling positive and negative symptoms of 
schizophrenia (Javitt and Zukin 1991; Krystal et al. 1994; Adler et al. 1999; Heresco-
Levy 2003; Krystal et al. 2003; Javitt 2010). Exposure to these compounds has been 
described to cause behavioral manifestations in rodents mimicking positive, negative, 
and cognitive features of schizophrenia (Carlsson and Svensson 1990; Tiedtke et al. 
1990; Riederer et al. 1991; Schmidt et al. 1991) and to trigger neuropathological changes 
that may represent the anatomic underpinnings of psychosis (Olney et al. 1999). This 
body of evidence has led to the formulation of the NMDA-R hypofunction (NRH) 
hypothesis of psychosis pathophysiology (Olney et al. 1999). NRH hypothesis predicts 
that a condition of NRH may induce complex dysfunctions in several neurotransmitter 
systems at both cortical and subcortical levels leading to information process failure and 
ultimately to psychotic symptoms (Moghaddam et al. 1997; Olney et al. 1999; Farber 
2003).  
Administration of antagonists at NMDA-Rs has been regarded as a valuable and 
heuristic animal model of psychosis (Lipska and Weinberger 2000). This 
pharmacological model is considered to have good predictive and construct validity 
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(Lipska and Weinberger 2000), allowing to identify new therapeutic targets and to study 
putative molecular dysfunctions implicated in psychosis.  
According to the view that glutamatergic transmission may be involved in psychosis 
pathophysiology, accumulating evidence is reporting the association of glutamatergic 
molecules to preclinical or clinical models of psychosis. Genes implicated in glutamate 
neurotransmission have been consistently associated to schizophrenia (de Bartolomeis et 
al. 2005). Mice carrying a deficit mutation of the NMDA-R NR1 subunit displayed 
behavioral abnormalities similar to those observed in  animal models of schizophrenia 
(Mohn et al. 1999). A reduction in NR1 subunit phosphorylation has been found in a 
subset of schizophrenic subjects (Li et al. 2009). Moreover, it has been observed that 
antipsychotics may alter gene expression and protein levels of molecules involved in 
glutamate transmission, as ionotropic glutamate receptors (Meador-Woodruff et al. 1996; 
Riva et al. 1997) or molecules of the PSD, as Homer. The PSD is a complex protein 
mesh located at the dendritic spines of post-glutamatergic neurons (de Bartolomeis et al. 
2005), that is implicated in synaptic signal transduction, neurotransmitters interplay, and 
in the regulation of ultrastructural architecture and functional organization of spines (de 
Bartolomeis et al. 2005). In recent studies, the inducible isoform of Homer1 gene 
resulted to be expressed after acute and chronic antipsychotic administration (Iasevoli et 
al. 2010; Iasevoli et al. 2010). Homer1a expression, indeed, was found to be triggered by 
selective antagonism on dopamine D2Rs (Iasevoli et al. 2009) as well as by ketamine 
administration (Iasevoli et al. 2007), suggesting that the pattern of Homer1a expression 
may be a powerful marker of glutamatergic and dopaminergic function and of their 
interplay.  
Recently, compounds acting on glutamatergic neurotransmission have been proposed 
and tested in the therapy of psychosis. Memantine is a derivative of amantadine acting 
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as NMDA-R partial uncompetitive antagonist (Johnson and Kotermanski 2006; Parsons 
et al. 2007). Memantine has been approved for clinical use in Alzheimer's disease. 
However, the drug is under investigation for use in several other conditions, including 
the use as add-on to antipsychotics in the treatment of refractory schizophrenia and for 
the improvement of cognitive failure in psychosis (Parsons et al. 2007; Zdanys and 
Tampi 2008).  
These clinical properties may derive from the peculiar pharmacological action of 
memantine. Memantine binds NMDA-R in a use-dependent and voltage-dependent way 
(Johnson and Kotermanski 2006; Parsons et al. 2007) in M2 region of NR1 and NR2 
subunits. Memantine acts as  a partial trapping blocker, probably because there are two 
binding sites in NMDA-R:  a deep site inside the external gate that allows full trapping, 
and a second shallow site outside the gate that may lead to a partial inhibition of channel 
closure, increasing channel in open state. Ketamine and MK-801 bind to the deep site, 
probably for this reason they have different profile compared to memantine (Johnson and 
Kotermanski 2006; Parsons et al. 2007). 
Under resting potential, -70mV, Mg++, memantine and MK-801 bind the NMDA-R. 
Both Mg++ and memantine may leave the channel upon strong depolarization, i.e.: -20 
mV, whereas MK-801 remains trapped. Memantine compared to Mg++ does not leave 
the channel upon moderate prolonged depolarization, i.e.: -50 mV, during chronic 
excitotoxic stimulus, as that induced by β amyloid (Parsons et al. 2007). While high 
affinity blockers, such as MK-801, block the pathological and physiological activation 
of NMDA-R, memantine decreases synaptic noise resulting from excessive NMDA-R 
activation, allows the physiological synaptic signaling and re-balances between 
inhibition and excitation of glutamate system (Parsons et al. 1999; Parsons et al. 2007; 
Gilling et al. 2009). Memantine prolongs duration of post-synaptic NMDA-R- 
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dependent Long-Term Potentation (LTP), important for neuronal memory (Johnson and 
Kotermanski 2006; Parsons et al. 2007). 
Moreover, memantine behaves as a dopamine D2R agonist that induces dopamine 
release in rat prefrontal cortex and striatum and reduces dopamine outflow in the 
hippocampus (Spanagel et al. 1994; Andreassen et al. 1996; Hesselink et al. 1999; 
Peeters et al. 2003; Giustizieri et al. 2007; Meisner et al. 2008; Seeman et al. 2008). 
Memantine upregulates mRNA and protein expression of the brain-derived neurotrophic 
factor (BDNF), and inhibits gene expression of Heat Shock Protein (HSP70) in hypoxic 
ischemia as protective effect (Caumont et al. 2006; Rosi et al. 2006; Shearman et al. 
2006). Indeed memantine reduces the rates of apoptosis in neuronal hypoxemic damage 
in the hippocampus and in the striatum (Chen et al. 1992; Block and Schwarz 1996; 
Ehrlich et al. 1999).  
In behavioral studies memantine does not induce hyperlocomotion at 5 mg/kg, while 10 
and 25 mg/kg doses cause small sustained increase in locomotion, as ketamine 
(Eisenberg et al. 1993; Gilmour 2009). At active lever pressing test memantine, as 
ketamine, decreases instrumental output with a dose-dependent effect (Gilmour 2009). 
In water maze test, memantine has been observed to improve hippocampus- based 
spatial learning in a transgenic mouse model of Alzheimer's Disease (Minkeviciene et 
al. 2004).  
Memantine may thus improve cognitive functions and may reveal beneficial in 
psychosis. However, memantine acts primarily on the same binding target of ketamine 
and MK-801, two compounds known to induce psychosis and used to model psychosis 
in animals (Bubenikova-Valesova et al. 2008). The aim of this study is to evaluate 
whether behaviorally active doses of memantine, ketamine, and MK-801 trigger 
changes in the gene expression of molecules of the PSD implicated in glutamate 
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signaling and dendrite functional status. Moreover, we wanted to verify whether 
putative molecular changes are similar or discrepant among the compounds tested, as to 
test the hypothesis that differences in behavioral outcomes among them may derive 
from the induction of different molecular responses, albeit acting on the same biological 
target.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
Results. 
Arc 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test, are 
detailed in Table 3; autoradiographic images are shown in Fig.13. A significant induction 
of Arc gene expression was observed in the anterior cingulate cortex (AC, ANOVA, 
p=0.0011; F(4,18)=8.1157); the premotor cortex (M2, ANOVA, p<0.0001; 
F(4,18)=13.6178); the motor cortex (M1, ANOVA, p<0.0001; F(4,18)=15.3103); the 
somatosensory cortex (SS, ANOVA, p<0.0001; F(4,17)=19.2305) and in the insular 
region (I, ANOVA, p<0.0001; F(4,17)=17.6433) following the treatment with 
memantine 5 mg/kg, MK-801 0.8 mg/kg, ketamine 25 mg/kg, ketamine 50 mg/kg, as 
compared to the vehicle. 
A significant induction of Arc gene expression was observed in the ventrolateral caudate 
putamen (VLCP, ANOVA, p=0.0288; F(4,16)=3.8229); in ventromedial caudate 
putamen (VMCP, ANOVA, p=0.0321; F(4,16)=3,6908); in the core of accumbens 
(Core, ANOVA, p=0.0026; F(4,16)=7.3206) following the treatment with ketamine 50 
mg/kg and MK-801 0.8 mg/kg as compared to the vehicle and in the shell of accumbens 
(Shell, ANOVA, p=0.0007; F(4,16)=9.7566) following the treatment with MK-801 0.8 
mg/ kg, ketamine 50 mg/kg and ketamine 25 mg/kg as compared to the vehicle. 
No significant changes in Arc expression were detected in dorsolateral caudate putamen 
(DLCP, ANOVA, p=0.1261; F(4,16)=2.1665) and in dorsomedial caudate putamen 
(DMCP, ANOVA, p=0.1170; F(4,16)=2.2399). 
 
c-fos 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test, are 
detailed in Table 4; autoradiographic images are shown in Fig.14. A significant induction 
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of c-fos gene expression was observed in the anterior cingulate cortex (AC, ANOVA, 
p=0.0082; F(4,16)=5.7201) following the treatment with MK-801 0.8 mg/kg; in the 
premotor cortex (M2, ANOVA, p=0.0026; F(4,16)=7.3356) following the treatment with 
MK-801 0.8 mg/kg, ketamine 50 mg/kg and memantine 5 mg/kg, as compared to the 
vehicle; in the insular region (I, ANOVA, p<0.0001; F(4,16)=39.8114) following the 
treatment with MK-801 0.8 mg/kg, ketamine 25 mg/kg, memantine 5 mg/kg and 
ketamine 50 mg/kg as compared to the vehicle. The treatment with ketamine 50 mg/kg 
significantly decreased c-fos expression as compared to the vehicle in the dorsolateral 
caudate putamen (DLCP, ANOVA, p=0.0104; F(4,16): 5.1450). In the ventrolateral 
caudate-putamen (VLCP, ANOVA, p=0.0025; F(4,16): 7.0750), the treatment with 
ketamine 50 mg/kg significantly decreased c-fos expression as compared to the vehicle, 
while the treatment with MK-801 0.8 mg/kg increased c-fos expression as compared to 
the vehicle. 
No significant changes in c-fos expression were detected in motor cortex (M1, ANOVA, 
p=0.1922; F(4,16)=1.7840), somatosensory cortex (SS, ANOVA, p=02750; 
F(4,16)=1.444); dorsomedial caudate putamen (DMCP, ANOVA, p=0.2139; 
F(4,16)=1.6814); ventromedial caudate putamen (VMCP, ANOVA, p=0.0560; 
F(4,16)=2.9908) and in nucleus accumbens (Core, ANOVA, p=0.0707; F(4,16)=2.7468; 
Shell, ANOVA, p=0.0322; F(4,16)=3.5977). 
 
Homer 1a 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test are 
detailed in Table 5; autoradiographic images are shown in Fig.15. Homer 1a gene 
expression was found decreased in the motor cortex (M1, ANOVA, p=0.0311; 
F(4,16)=3.7306); in somatosensory cortex (SS, ANOVA, p=0.0023; F(4,16)=7.5474) 
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following the treatment with memantine 5 mg/kg and ketamine 50 mg/kg as compared 
to the vehicle.  Homer 1a increased following the treatment with memantine 5 mg/kg as 
compared to the vehicle, and decreased following the treatment with ketamine 25 mg/kg 
as compared to the vehicle; in insular region (I, ANOVA, p=0.0155; F(4,16)=4.6095) 
following the treatment with ketamine 25 mg/kg, as compared to the vehicle. 
No significant changes in Homer 1a expression were detected in anterior cingulate 
cortex (AC, ANOVA, p=0.0411; F(4,16)=3.4027), premotor cortex (M2, ANOVA, 
p=0.1433; F(4,16)=2.0706); dorsolateral caudate putamen (DLCP, ANOVA, p=0.1371; 
F(4,16)=2.1490); dorsomedial caudate putamen (DMCP, ANOVA, p=0.0870; 
F(4,16)=2.5783); ventromedial caudate putamen (VMCP, ANOVA, p=0.2279; 
F(4,16)=1.6214); ventrolateral caudateputamen (VLCP, ANOVA, p=0.02070; 
F(4,16)=4.2348) and in nucleus accumbens (Core, ANOVA, p=0.0832; 
F(4,16)=2.6253; Shell, ANOVA, p=0.3921; F(4,16)=1.1126). 
 
Homer 1b 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test are 
detailed in Table 6; autoradiographic images are shown in Fig.16. Homer 1b gene 
expression was found decreased in premotor cortex (M2, ANOVA, p=0.0265; 
F(4,16)=3.7385), following the treatment with ketamine 50 mg/kg as compared to the 
vehicle; in motor cortex (M1, ANOVA, p=0.0023; F(4,16)=6.9258) following the 
treatment with ketamine 25 mg/kg and ketamine 50 mg/kg, as compared to the vehicle. 
In the dorsolateral caudate putamen (DLCP, ANOVA, p=0.0249, F(4,17)=3.7345) 
Homer 1b gene expression was decreased by the treatment with ketamine 25 mg/kg and 
50 mg/kg as compared to the vehicle. 
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No significant changes in Homer 1b expression were detected in anterior cingulate 
cortex (AC, ANOVA, p=0.2988; F(4,16)=1.3459); somatosensory cortex (SS, ANOVA, 
p=0.1122; F(4,17)=2.2249); insular region (I, ANOVA, p=0.0680; F(4,17)=2.7019); 
dorsomedial caudate putamen (DMCP, ANOVA, p=0.3897; F(4,17)=1.1012); 
ventromedial caudate putamen (VMCP, ANOVA, p=0.4963; F(4,17)=0.8826); 
ventrolateral caudate putamen (VLCP, ANOVA, p=0.3642; F(4,17)=1.1617) and in 
nucleus accumbens (Core, ANOVA, p=0.2058; F(4,17)=1.6705; Shell, ANOVA, 
p=0.9905; F(4,17)=0.0688). 
 
PSD95 
Results, with respective ANOVA values and Student-Newman-Keuls post hoc test are 
detailed in Table 7; autoradiographic images are shown in Fig.17. A significant decrease 
of PSD95 gene expression was observed in the dorsomedial caudate putamen (DMCP, 
ANOVA, p=0.0270; F(4,15)=3.8006) following the treatment with ketamine 25 mg/kg, 
ketamine 50 mg/kg, MK-801 0.8 mg/kg, as compared to the vehicle; in the dorsolateral 
caudate putamen (DLCP, ANOVA, p=0.0158; F(4,15)=4.4457) and in the .entromedial 
caudate putamen (VMCP, ANOVA, p=0.0431; F(4,15)=3.2747) following the 
treatment with MK-801 0.8 mg/kg, as compared to the vehicle. 
No significant changes in PSD95 expression were detected in anterior cingulate cortex 
(AC, ANOVA, p=0.2119; F(4,15)=1.6903); premotor cortex (M2, ANOVA, p=0.0682; 
F(4,15)=2.8369); motor cortex (M1, ANOVA, p=0.5807; F(4,15)=0.7411); 
somatosensory cortex (SS, ANOVA, p=0.0448; F(4,15)=3.2306); insular region (I, 
ANOVA, p=0.4740; F(4,15)=0.9311); ventrolateral caudate putamen (VLCP, ANOVA, 
p=0.5887; F(4,15)=0.7261); and in nucleus accumbens (Core, ANOVA, p=0.1326; 
F(4,15)=2.1179; Shell, ANOVA, p=0.2995; F(4,15)=1.3638). 
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Table 3. mRNA levels of Arc after acute ketamine treatment. Data are expressed as 
d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain regions analyzed, 
along with the relative ANOVA (degrees of freedom and p values). Significant p values 
are expressed in bold. Post-hoc test: * significantly higher expression compared to 
VEH.   
 
Arc Memantine MK-801 Ket 50 Ket 25 Veh 
ANOVA 
(p, F) 
Frontal cortex       
Anterior 
Cingulate cortex 
45.7057± 
1.8611* 
45.5374± 
1.4107* 
50.0785± 
1.0328* 
53.9778± 
2.3036* 
38.5084 
3.0334 
p = 0.0011, 
F4.15 = 8.1157 
Medial 
Agranular 
Cortex 
49.4633± 
3.3249* 
43.1678± 
2.1047* 
53.5718± 
0.6293* 
55.7157± 
3.0262* 
35,8497 
1,4005 
p < 0.0001, 
F4.15 =13.6178 
Motor Cortex 
46.6217± 
5.0033* 
44.8029± 
1.5637* 
56.1015± 
1.5651* 
51.4047± 
1.0699* 
34,3722 
1,2674 
p < 0.0001, 
F4.15 = 
15.3103 
Somatosensory 
Cortex 
47.4757± 
5.3192* 
43.7932± 
2.4391* 
56.0727± 
1.4725* 
54.6354± 
0.5926* 
31,6188 
0,9341 
p < 0.0001, 
F4.14 = 9.2305 
Insular Cortex 
44.9480± 
4.0336* 
42.5406± 
2.9450* 
50.1640± 
1.2240* 
46.7972± 
1.7877* 
26,0336 
1,3166 
p < 0.0001, 
F4.14 = 7.6433 
Striatum       
Dorsomedial 
Caudate 
Putamen 
31,1330± 
3,6284 
36,4460± 
1,5252 
38,0892± 
1,0713 
33,5373± 
2,2610 
32,0128 
1,2751 
p > 0.05,  
F4.14 = 2.1665 
Dorsolateral 
Caudate 
Putamen 
32,6113± 
4,2183 
35,9424± 
1,2429 
36,5855± 
0,9622 
29,3330± 
2,8426 
31,1127 
1,1421 
p > 0.05,  
F4.14 = 2.2399 
Ventromedial 
Caudate 
Putamen 
32,6187± 
3,6894 
36.7593± 
0.8953* 
36.2430± 
0.8554* 
29,4750± 
1,9739 
28,6124 
1,8427 
p = 0.0321, 
F4.13 = 3.6908 
Vetrolateral 
Caudate 
Putamen 
32,7287± 
3,7792 
35.8753± 
1.0140* 
34.9005± 
1.1229* 
27,1395± 
3,1993 
26,2960 
1,1554 
p = 0.0288, 
F4.13 = 3.8229 
Core of the 
Nucleus 
Accumbens 
25,4760± 
2,8837 
34.6110± 
0.2733* 
35.5977± 
1.6234* 
24,5585± 
3,4390 
21,2612 
1,9769 
p = 0.0026, 
F4.13 = 7.3206 
Shell of the 
Nucleus 
Accumbens 
24,6173± 
1,5475 
35.3390± 
1.0944* 
34.3397± 
0.7047* 
27.1208± 
3.8803* 
19,2241 
1,0891 
p = 0.0007, 
F4.13 = 9.7566 
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Figure 13. Autoradiographic image and graphics of Arc mRNA expression in Frontal 
Cortex, Striatum, Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
 
Veh Mem MK-801 Ket25 Ket50 
 72 
 
Table 4. mRNA levels of c-fos after acute ketamine treatment. Data are expressed as 
d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain regions analyzed, 
along with the relative ANOVA (degrees of freedom and p values). Significant p values 
are expressed in bold. Post-hoc test: * significantly higher expression compared to 
VEH.   
 
 
 
 
 
c-fos Memantine MK-801 Ket 50 Ket 25 Veh 
ANOVA 
(p, F) 
Frontal cortex       
Anterior 
Cingulate cortex 
136,606± 
3,464 
175.985± 
19.983* 
140,892± 
3,339 
139.445±  
4.7039 
119,714± 
4,092 
p = 0.0082, 
F4.12 = 5.7201 
Medial 
Agranular 
Cortex 
135.413±  
5.7543* 
153.261±  
3.9777* 
139,445± 
4,7039* 
130,578± 
2,9979 
121,511± 
3,7471 
p = 0.0026, 
F4.13 =  7.3356 
Motor Cortex 
122,552± 
2,166 
135,821± 
7,738 
132,064± 
10,386 
126,965± 
8,819 
110,111± 
2,320 
p > 0.05, 
 F4.13 = 1.7840 
Somatosensory 
Cortex 
130,236± 
3,963 
121,820± 
14,100 
113,156± 
10,133 
128,962± 
8,061 
107,005± 
2,725 
p > 0.05, F4.13 
=  1.4440 
Insular Cortex 
123.603±  
3.8190* 
169.713±  
2.7242* 
122.694±  
3.3360* 
127.268±  
5.3554* 
100,911± 
2,3835 
p < 0.0001, 
F4.13 = 9.8114 
Striatum       
Dorsomedial 
Caudate 
Putamen 
102,387± 
3,829 
106,756± 
10,493 
80,484± 
8,450 
90,304± 
10,337 
97,785± 
2,623 
p = 0.0104, 
F4.13 =  5.1450 
Dorsolateral 
Caudate 
Putamen 
101,963± 
5,3429 
100,988± 
8,1072 
70,665± 
7,9377* 
77,892± 
6,0444 
94,021± 
1,7614 
p > 0.05,  
F4.13 =  1.6814 
Ventromedial 
Caudate 
Putamen 
98,237± 
4,426 
107,766± 
10,070 
77,536± 
7,560 
82,560± 
7,792 
96,511± 
1,870 
p > 0.05, 
 F4.14 = 2.9908 
Vetrolateral 
Caudate 
Putamen 
101,299± 
6,3708 
108.627±  
8.2715* 
65.746±  
7.3540* 
78,777± 
6,7156 
89,150± 
0,2270 
p = 0.0025, 
F4.14 =  7.0750 
Core of the 
Nucleus 
Accumbens 
98,425± 
2,970 
108,824± 
3,564 
75,013± 
7,997 
85,932± 
9,262 
91,798± 
10,223 
p > 0.05, 
 F4.14 = 2.7468 
Shell of the 
Nucleus 
Accumbens 
100,714± 
8,4896 
119,155± 
8,1766 
76,154± 
9,2383 
87,611± 
8,1134 
99,219± 
8,8841 
p > 0.05, 
 F4.14 = 3.5977 
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Figure 14. Autoradiographic image and graphics of c-fos mRNA expression in Frontal 
Cortex, Striatum, Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Table 5. mRNA levels of Homer 1a after acute ketamine treatment. Data are 
expressed as d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain 
regions analyzed, along with the relative ANOVA (degrees of freedom and p values). 
Significant p values are expressed in bold. Post-hoc test: * significantly higher 
expression compared to VEH.   
 
 
 
 
Homer1a Memantine MK-801 Ket 50 Ket 25 Veh 
ANOVA 
(p, F) 
Frontal cortex       
Anterior 
Cingulate cortex 
72,7529± 
4,2285 
72,3036± 
0,6897 
59,0510± 
3,4561 
85,7285±  
7,3110 
74,6634± 
6,3213 
p = 0,0411, 
F4.13 =  3,4027 
Medial 
Agranular 
Cortex 
64,5386±  
6,6267 
77,3206±  
6,5160 
63,5037± 
3,1073 
81,4304± 
5,7097 
79,5713± 
7,5011 
p > 0.05,  
F4.13 =  2,0706 
Motor Cortex 
67,7075±  
7,1902* 
79,6898± 
3,3459 
72,2832± 
4,4806* 
87,9380± 
3,8759 
86,4840± 
3,7012 
p = 0,0311, 
F4.13 =  3,7306 
Somatosensory 
Cortex 
62,1118±  
 3,4920* 
71,3270± 
3,5840 
64,8863± 
2,1594 
82,1247± 
2,4296* 
72,8547± 
3,0079 
p = 0,0023, 
F4.13 =  7,5474 
Insular Cortex 
73,3346±  
 7,8146* 
74,5933±  
3,1371 
69,2346±  
2,2896 
87,5793±  
1,3393* 
66,0218± 
4,6099 
p = 0,0155, 
F4.13 =  4,6095 
Striatum       
Dorsomedial 
Caudate 
Putamen 
54,8060± 
4,4133 
60,0616± 
0,1218 
50,9906± 
4,1770 
67,2087± 
3,6108 
59,2727± 
4,5427 
p > 0.05, 
 F4.13 = 2,5783 
Dorsolateral 
Caudate 
Putamen 
41,2143± 
13,902 
57,0164± 
1,194 
48,3230± 
3,281 
65,5899± 
5,709 
58,3051± 
2,515 
p > 0.05,  
F4.12 =  2,1490 
Ventromedial 
Caudate 
Putamen 
56,0508± 
2,6991 
55,9778± 
1,2748 
51,5136± 
6,7559 
66,3797± 
3,7985 
63,8692± 
5,8372 
p > 0.05,  
F4.13 =  1,6214 
Vetrolateral 
Caudate 
Putamen 
52,9175± 
5,5881 
57,5880±  
4,4012 
46,5360±  
2,8874 
65,4463± 
2,4300 
56,4579± 
2,9212 
p > 0.05, 
 F4.13 = 4,2348 
Core of the 
Nucleus 
Accumbens 
55,2001± 
3,8810 
62,2923± 
1,7102 
49,9710± 
2,9031 
64,9129± 
5,1978 
62,5464± 
4,0793 
p > 0.05, 
 F4.13 = 2,6253 
Shell of the 
Nucleus 
Accumbens 
49,4300± 
6,1049 
55,3990± 
1,4661 
48,0909± 
3,9456 
60,7672± 
6,0609 
51,4509± 
5,0991 
p > 0.05, 
 F4.13 = 1,1126 
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Figure 15. Autoradiographic image and graphics of H1a mRNA expression in Frontal 
Cortex, Striatum, Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Table 6. mRNA levels of Homer 1b after acute ketamine treatment. Data are 
expressed as d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain 
regions analyzed, along with the relative ANOVA (degrees of freedom and p values). 
Significant p values are expressed in bold. Post-hoc test: * significantly higher 
expression compared to VEH.   
 
Homer1b Memantine MK-801 Ket 50 Ket 25 Veh 
ANOVA 
(p, F) 
Frontal cortex       
Anterior 
Cingulate cortex 
118,282± 
4,0404 
108,031± 
5,7465 
107,061± 
1,2546 
116,450±  
5,2734 
114,845± 
4,1309 
p > 0.05, 
F4.15 =  1,3459 
Medial 
Agranular 
Cortex 
131,953±  
2,7887 
124,773±  
5,9981 
109,228± 
3,2945* 
119,030± 
8,0328 
131,765± 
1,7012 
p = 0,0265, 
F4.15 =  3,7385 
Motor Cortex 
123,335± 
 2,0169* 
119,330± 
6,4513 
100,388± 
1,5271* 
109,222± 
6,1989* 
128,350± 
2,2492 
p = 0,0023, 
F4.13 =  6,9258 
Somatosensory 
Cortex 
118,668±  
3,1867 
115,048± 
3,1126 
104,508± 
3,6391 
108,251± 
7,7392 
119,459± 
2,1100 
p > 0.05, 
F4.16 =  2,2249 
Insular Cortex 
122,942±  
 0,6542 
121,780±  
4,9081 
107,304±  
3,2584 
119,187±  
5,5163 
123,777± 
3,0918 
p > 0.05, 
F4.16 =  2,7019 
Striatum       
Dorsomedial 
Caudate 
Putamen 
100,578± 
2,8868 
106,435± 
4,1457 
99,281± 
5,4546 
97,534± 
3,0980 
108,007± 
5,5382 
p > 0.05, 
F4.16 = 1,1012 
Dorsolateral 
Caudate 
Putamen 
110,250± 
4,7136 
111,475± 
6,2786 
97,478± 
4,3687* 
103,625± 
4,1704* 
124,283± 
4,4151 
p =0,0249 , 
F4.16 =  3,7345 
Ventromedial 
Caudate 
Putamen 
111,618± 
5,9833 
115,529± 
3,2496 
113,317± 
5,6941 
107,563± 
3,3377 
118,657± 
3,1007 
p > 0.05, 
F4.16 = 0,8826 
Vetrolateral 
Caudate 
Putamen 
118,659± 
2,1440 
124,462±  
5,3995 
110,342±  
6,3813 
112,226± 
7,7323 
123,203± 
6,5800 
p > 0.05, 
F4.16 = 1,1617 
Core of the 
Nucleus 
Accumbens 
118,488± 
3,4276 
114,967± 
3,2929 
111,884± 
5,1188 
109,349± 
3,7718 
122,151± 
3,6071 
p > 0.05, 
 F4.16 = 1,6705 
Shell of the 
Nucleus 
Accumbens 
91,7777± 
3,157 
89,0715± 
9,794 
93,2689± 
9,663 
87,3565± 
3,974 
92,8403± 
15,500 
p > 0.05,  
F4.16 = 0,0688 
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Figure 16. Autoradiographic image and graphics of H1b mRNA expression in Frontal 
Cortex, Striatum, Nucleus Accumbens expressed in relative dpm as mean ± S.E.M.; 
*ANOVA p<0,05 vs VEH. 
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Table 7. mRNA levels of PSD95  after acute ketamine treatment. Data are expressed 
as d.p.m. mean valuesstandard error means (S.E.M.) and listed by brain regions 
analyzed, along with the relative ANOVA (degrees of freedom and p values). 
Significant p values are expressed in bold. Post-hoc test: * significantly higher 
expression compared to VEH.   
 
 
 
 
PSD95 Memantine MK-801 Ket 50 Ket 25 Veh 
ANOVA 
(p, F) 
Frontal cortex       
Anterior 
Cingulate cortex 
194,858± 
1,9492 
174,968± 
4,4275 
193,219± 
2,6314 
185,995±  
7,4056 
192,808± 
5,3335 
p > 0.05, F4.13 
=  1,6903 
Medial 
Agranular 
Cortex 
190,192±  
2,8010 
183,609±  
5,3810 
187,529± 
3,3665 
180,433± 
2,8656 
192,790± 
1,2344 
p > 0.05, F4.13 
=  2,8369 
Motor Cortex 
179,688± 
5,2426 
176,066± 
6,8308 
174,621± 
5,2798 
175,396± 
3,9123 
183,763± 
2,0368 
p > 0.05, F4.13 
=  0,7411 
Somatosensory 
Cortex 
173,307± 
3,1913 
167,065± 
3,0244 
172,856± 
3,5797 
173,520± 
2,1787 
180,109± 
1,5104 
p > 0.05, F4.14 
=  3,2306 
Insular Cortex 
191,434± 
2,0232 
184,708±  
3,5258 
191,297±  
0,2318 
183,562±  
4,2627 
186,233± 
4,0871 
p = 0,4740, 
F4.14 =  0,9311 
Striatum       
Dorsomedial 
Caudate 
Putamen 
177,538± 
3,0961 
170,670± 
2,4602* 
175,9053±  
2,9123* 
176,473±  
2,1923* 
185,297± 
3,2757 
p =0,0270 , 
F4.14 =  3,8006 
Dorsolateral 
Caudate 
Putamen 
182,199± 
3,3377 
166,778± 
1,7327* 
174,647± 
3,4661 
174,046± 
3,6187 
181,402± 
1,5383 
p =0,0158 , 
F4.14 =  4,4457 
Ventromedial 
Caudate 
Putamen 
186,929± 
4,0533 
168,983± 
2,8131* 
180,164± 
1,0510 
179,676± 
4,2777 
183,647± 
3,6382 
p =0,0431, 
F4.14 =  3,2747 
Vetrolateral 
Caudate 
Putamen 
188,993± 
3,6656 
178,758±  
3,9901 
183,346±  
3,8891 
186,202± 
4,8988 
181,942± 
4,5282 
p > 0.05, F4.14 
=  0,7261 
Core of the 
Nucleus 
Accumbens 
192,150± 
0,6204 
180,430± 
0,6946 
188,528± 
2,0450 
190,689± 
4,5539 
190,039± 
2,9205 
p > 0.05, F4.14 
=  2,1179 
Shell of the 
Nucleus 
Accumbens 
179,294± 
5,6548 
180,132± 
3,3519 
178,496± 
6,0050 
175,140± 
5,6075 
191,149± 
1,6767 
p > 0.05, F4.13 
=  1,3638 
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Figure 17. Autoradiographic image and graphics of PSD95 mRNA expression in 
Frontal Cortex, Striatum, Nucleus Accumbens expressed in relative dpm as mean ± 
S.E.M.; *ANOVA p<0,05 vs VEH. 
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Chapter 6. 
Discussion. 
In the first paradigm studied herein, we aimed to gain knowledge into the putative 
connection between psychosis and glucose metabolism. Therefore, we chose to treat rats 
with sub-anesthetic doses of ketamine, a compound assumed to provide a 
pharmacological animal model of psychosis by its action as a non-competitive 
antagonist of glutamatergic NMDA-Rs (Bubenikova-Valesova et al. 2008). Beyond its 
action on neurotransmitter systems, ketamine is believed to induce psychosis-
resembling behaviors in rodents by triggering neurotoxic damage and apoptosis in 
selected brain areas (Green and Cote 2009).  
In this model, we chose to study the expression of Hk1 and GLUT3 genes, which code 
for the brain-specific isoforms of these molecules and may be considered candidate 
genes for both psychosis and glucose metabolism dysfunctions (Prabakaran et al. 2004; 
McDermott and de Silva 2005; Robey and Hay 2006; Martins-de-Souza et al. 2009; 
Martins-De-Souza et al. 2010).  
We have found that ketamine dose-dependently affects the expression of both Hk1 and 
GLUT3 in a region-specific fashion and may change the topographic distribution of 
gene expression in the regions of interest when compared to basal distribution. The 
neurotoxic dose of ketamine (50 mg/kg) has been observed to increase Hk1 gene 
expression in several cortical and subcortical areas, while the non-neurotoxic dose (12 
mg/kg) did not affect increased Hk1 expression in the majority of regions studied 
auditory cortex only. On the contrary, GLUT3 expression was decreased by the 50-
mg/kg dose of ketamine has been shown to decrease GLUT3 expression in the 
retrosplenial cortex and in striatum, lateral septum, and frontal cortex subcortical areas 
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and increased by 12 mg/kg ketamine in the frontal cortex and the striatum (although in 
this latter region compared to KET50 only). 
These findings appear to confirm the view that Hk1 and GLUT3 may be implicated in 
ketamine-induced metabolic dysfunctions and may play a role in molecular mechanisms 
of psychosis. As ketamine acts preferentially as an antagonist of NMDA-Rs, it could be 
hypothesized that glutamate perturbation may secondarily affect glucose metabolism, 
thereby stimulating Hk1 expression as a feedback compensatory mechanism. Consistent 
with this view, a reduction of glycolysis has been found in cortical areas of rats treated 
with MK-801, another NMDA-R antagonist believed to provide a pharmacological 
model of psychosis (Eyjolfsson et al. 2011). Moreover, hypoglycemia has been 
associated with enhanced cortical expression of genes coding for NMDAR1, NMDA2B 
and mGlu5 receptors (Joseph et al. 2008). Glutamatergic synapses have recently 
received great attention as putative sites of lesions in psychosis pathophysiology (Olney 
et al. 1999). In our previous studies, we have observed that the expression of the 
immediate early-gene Homer1a is modulated by antipsychotics (Iasevoli et al. 2010) 
and by a dopamine D2R selective antagonist (Iasevoli et al. 2009) as well as by 
ketamine (Iasevoli et al. 2007). These observations lend further support to the view that 
molecules involved in glutamatergic neurotransmission within glutamatergic synapses 
may be implicated in the pathophysiology of psychosis or in the molecular mechanisms 
of action of anti-psychotic drugs. Hk1 may thus represent a novel molecular target to 
study glutamatergic dysfunctions in psychosis.   
Increased Hk1 expression may also represent a mechanism to escape neurotoxic damage 
and apoptosis induced by ketamine. Ketamine is known to induce apoptosis in neuronal 
cell lines via the mitochondrial pathway (Braun et al. 2010) and sub-anesthetic ketamine 
has been found to trigger mitochondrial dysfunctions in prefrontal cortex, striatum and 
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hippocampus of rats (de Oliveira et al. 2011). Intriguingly, Hk1 competes with the pro-
apoptotic Bax/Bak factors to interact with mitochondria (Pastorino et al. 2002). 
Detachment of Hk1 from mitochondria may facilitate binding to Bax/Bak and may dys-
regulate mitochondrial VDAC functions (Gottlieb et al. 2003), both phenomena 
promoting apoptosis. Induction of apoptosis has been associated with decreased Hk1 
association with mitochondria (Gottlieb 2001). Thus, increase of Hk1 gene expression 
increase by ketamine may imply a compensatory mechanism for triggered by activation 
of apoptotic pathways. The preferential increase by the neurotoxic dose of ketamine 
appears to support this suggestion. Notably, Hk1 expression has been found reduced in 
schizophrenia brain tissue (Prabakaran et al. 2004; Martins-de-Souza et al. 2009). It 
could be hypothesized that reduced or insufficient Hk1 expression may fail prevention 
of apoptosis and thus predispose to neurotoxic damage, which has been accounted for 
schizophrenia pathophysiology. 
Although ketamine has been shown to increase Hk1 gene expression according to a 
region-specific distribution, the pattern of Hk1 gene expression is strikingly divergent 
from that of other genes, e.g. the immediate-early gene c-fos (Imre et al. 2006). This 
peculiar pattern may depend on superior sensitivity of some brain areas compared to 
others in terms of ketamine-mediated dysfunctions, at least in glucose metabolism. 
Indeed, auditory and retrosplenial cortex appeared to be a sensible brain areas, as Hk1 
expression has been found increased by both drug doses and gene expression 
distribution was significantly modified compared to basal distribution by ketamine 
administration.  
Auditory, visual and retrosplenial cortices, as well as several aspects of striatum belong 
to a complex neuronal network controlling and influenced by emotive and cognitive 
behavior (Lang et al. 1998; Maddock 1999; Radwanska et al. 2010; Simpson et al. 
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2010; Plichta et al. 2011). Hk1 expression in these areas was more consistently affected 
by ketamine compared to sensor-motor regions, e.g.: subregions of the frontal cortex. 
Disruption of working memory, cognitive tasks, as well as induction of emotional 
blunting have been described in rats exposed to ketamine (Imre et al. 2006; Pietersen et 
al. 2007) and ketamine administration has been proposed as an effective model of 
cognitive deficits and negative symptoms of schizophrenia (Krystal et al. 1994; Neill et 
al. 2010). The results of this study may suggest that ketamine prominently induces 
neurotoxic damage in brain regions implicated in the regulation of emotive and 
cognitive behavior. More studies are needed to test this hypothesis.  
It has been observed that GLUT3 surface expression and glucose import is enhanced by 
synaptic stimulation in cultured cortical and hippocampal neurons. This effect is 
counteracted by inhibition of NMDA-Rs, thus demonstrating that activation of NMDA-
Rs increases GLUT3 surface expression and activity (Ferreira et al. 2011). The lack or 
the reduction of GLUT3 gene increase by ketamine described herein seems to be 
consistent with these observations. Taken together, these results let hypothesize that 
GLUT3 may tune glucose uptake into neurons in relation to the extent of NMDA-R-
mediated activation.  
In the second paradigm of this study, we explored putative changes in genes relevant for 
dopamine signaling, namely the genes coding for dopamine D1R and D2R and for 
DAT, after either acute or subchronic exposure to systemic ketamine. The rationale for 
this study stems from the observations that ketamine, and other NMDA-R antagonists, 
may induce a psychotic state in humans and schizophrenia-resembling behaviors in 
rodents that are reverted by anti-dopaminergic agents, as antipsychotics (Lipska and 
Weinberger 2000). Indeed, NMDA-R antagonists as ketamine are known to affect 
dopamine release and turnover (Javitt 2010) and possibly dopamine signaling. 
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Moreover, it has been suggested that acute NMDA-R blockade may resemble acute 
psychotic symptoms while subchronic antagonism at NMDA-Rs may best model long-
lasting cognitive and molecular changes occurring in psychosis (Krystal et al. 1994; 
Neill et al. 2010). Thereby, we wanted to investigate whether putative gene changes 
may be different in acute vs. subchronic ketamine administration.    
Dopamine D1R expression was decreased by acute ketamine in the lateral caudate-
putamen and in the core of the accumbens while expression in the cortex was not 
significantly changed. Dopamine D2R expression was not affected by acute ketamine. 
After subchronic exposure to ketamine, however, D1R expression was not affected in 
any of the region assessed, while D2R expression was increased in the ventrotegmental 
area and DAT expression was increased in the ventrotegmental area and the substantia 
nigra pars compacta. Both the temporal and topographic profile of gene expression 
changes are suggestive of feedback adaptations in dopamine system occurring as a 
consequence of ketamine-induced dopamine perturbation and aiming at preserving 
homeostasis. 
The results described above suggest that acute response to ketamine takes place with 
regard to dopamine gene expression changes at postsynaptic sites, while presynaptic 
feedback mechanisms could be activated after prolonged exposure to ketamine. 
Moreover, the results seem also to suggest that subcortical areas may be more sensitive 
than cortical areas to the effects of ketamine-mediated dopaminergic dysfunction, at 
least in terms of adaptive changes of gene expression.  
Acute ketamine has been described to induce dopamine release in both cortex and 
striatum (Verma and Moghaddam 1996). Decrease of D1R expression in striatal 
subregions may be due to a mechanism of regulation putatively induced by the 
dopaminergic subcortical overstimulation promoted by acute ketamine administration. 
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The lack of relevant D1R expression changes in cortex may imply that mechanisms 
different from changes in gene expression may take place in this region to compensate 
hyperdopaminergia. Moreover, it may be not excluded that increased activity of D1 
receptors may represent a beneficial mechanism to counteract ketamine-induced 
NMDA-R hypofunction. Indeed, it has been demonstrated that NMDA and D1 receptors 
may interact physically and functionally (Kruse et al. 2009). Indeed, there is some 
evidence that increasing D1R activity in the prefrontal cortex enhances NMDA-R 
function (Li et al. 2010), while in hippocampal neurons activation of D1R has been 
shown to upregulate NMDA-R-mediated LTP (Nai et al. 2010).  
In the subchronic paradigm, the absence of significant changes in the expression of 
post-synaptic D1R is consistent with the view that prolonged exposure to ketamine and 
prolonged hyperdopaminergia may be best counteracted by presynaptic rather than 
postsynaptic mechanisms, once these have failed to revert hyperdopaminergia. Indeed,  
the increase of DAT and D2R expression in the subchronic paradigm is consistent with 
this view.  
These data are in agreement with previous studies. It has been suggested that chronic 
ketamine may induce functional hypersensitivity of dopamine-releasing mechanisms, 
probably through increased sensitivity of DAT located on pre-synaptic dopaminergic 
neurons. These presynaptic mechanisms, at least partially and at level of transcription, 
could underlie the facilitation of stimulus-related dopamine release induced by 
ketamine. 
Considering previous evidence of direct modulation of DAT function by D2R 
autoreceptor, our results could fit with the above-mentioned hypothesis. Subchronic 
administration of ketamine may augment the effects of psychostimulants in drug-abuse 
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situations. Similar pre-synaptic hypersensitivity could contribute to the development of  
“endogenous sensitization” in the pathophysiology of psychosis. 
In humans, ketamine has been shown to increase dopamine release in striatum and to 
sensitize dopamine system, enhancing amphetamine-mediated dopamine release 
(Kegeles et al. 2000). Albeit acting on glutamate transmission, ketamine induces 
profound changes in dopamine signalling, consistent with its potential to elicit psychotic 
symptoms in healthy humans and to exacerbate psychosis in stable schizophrenics. 
Nonetheless, molecular changes in dopamine system after acute or chronic ketamine 
administration are poorly understood, also because of ethical issues in studying chronic 
ketamine in human experiments. The depiction of molecular changes in a condition of 
ketamine-induced hyperdopaminergia may have great relevance as they may resemble 
those putatively occurring in schizophrenia pathophysiology. The picture emerging 
from the experiments carried out in this study suggests that striatum and midbrain are 
more interested than cortical regions, at least in terms of gene expression, in a condition 
of ketamine-mediated dopamine perturbation and that postsynaptic mechanisms may 
represent a first line adaptations that may be replaced by presynaptic mechanisms once 
failed to revert hyperdopaminergia.  
 
Administration of a set of NMDA-R antagonists has been found to trigger different 
changes in the expression of genes involved in glutamate signaling, neuronal 
functioning, and marking neuronal activity status (i.e.: Homer 1a, Arc, Homer 1b, 
PSD95 and c-fos). The differences in gene expression observed in this study are 
consistent with the different clinical and preclinical profile of these compounds, albeit 
their apparently similar pharmacological mechanisms. It appears that the different 
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NMDA-R antagonists used may activate divergent post-receptor pathways of signal 
transduction and neuronal activation and may act on different brain regions.  
Ketamine and MK-801 induce a psychotic state in humans and schizophrenia-
resembling behaviors in animals and are widely used to provide animal models of the 
disease. On the other hand, the NMDA-R antagonist memantine is currently in use as a 
therapeutic agent in cognitive failure and has been proposed in the treatment of negative 
and cognitive symptoms of schizophrenia, as add-on to traditional antipsychotics. 
According to the prevalent pro-cognitive action of the compound, memantine affects 
gene expression exclusively in cortical areas. Non-competitive NMDA-R antagonists, 
above all MK-801 and the neurotoxic subanaesthetic dose of ketamine, affect the 
expression of both inducible and constitutive genes in both cortical and subcortical 
areas, a feature that is consistent with the strong locomotor action by these compounds 
(de Bartolomeis and Iasevoli 2003; Iasevoli et al. 2007). Arc and c-fos expression are 
increased by memantine in the cortex, presumably as a consequence of neuronal 
activation in this area. Arc expression is increased in ventral striatum by ketamine 
50mg/kg and MK-801. Arc protein interacts with proteins involved in clathrin-mediated 
endocytosis and facilitates the removal of AMPA-R from the membrane (Chowdhury et 
al. 2006; Bloomer et al. 2007). These plastic changes could modulate synaptic 
activation and prevent hyper-activation/neurotoxicity of glutamatergic neurons, 
important for learning and memory (McIntyre et al. 2005). It may be expected that, 
beyond marking neuronal activation, the relevant Arc induction by ketamine and MK-
801 may also have a mechanistic value, in order to prevent hyper-activation of 
postsynaptic receptors. 
Expression of the inducible gene Homer1a is decreased rather than induced by 
memantine. In previous studies, expression of Homer1a has been found increased by 
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the non-competitive antagonist ketamine and by antagonism at D2Rs. Homer1a 
expression has been conceptualized as being influenced by glutamate action onto non-
NMDA-Rs and by dopamine action onto D1Rs. Although blocking NMDA-Rs, 
memantine action may be best simplified as consisting in a partial agonism at NMDA-
Rs (Johnson and Kotermanski 2006), thus suggesting a state of functional 
agonism/antagonism depending on endogenous glutamate activity. It is expected that 
memantine may not cause a condition of NMDA-R hypofunction, as that described for 
ketamine, and thus it may not induce paradoxical hyperglutamatergia onto non-NMDA-
Rs. Moreover, memantine has been described to exert agonist action at D2Rs. These 
features may explain the lack of Homer 1a induction or its reduction by memantine. 
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Conclusions: 
In the studies described here, we have explored the effect of ketamine, as a NMDA-R 
antagonist providing a powerful animal model of psychosis, on key genes of dopamine 
and glutamate postsynaptic neurotransmission, neuronal activation, and glucose 
metabolism in neurons. Our aim was to investigate the molecular changes putatively 
occurring in multiple biological systems in an animal model that has been widely used 
to resemble psychotic-like behaviors in preclinical paradigms and that is considered to 
have high heuristic, construct, and predictive validity (Lipska and Weinberger 2000). 
Overall, the results show that ketamine administration may be associated with adaptive 
changes in glucose metabolism and dopamine signaling. Glucose metabolism may be 
impaired by ketamine, causing an increase in the expression of Hk1 gene (coding for the 
enzyme catalyzing glycolysis), and a decrease in the expression of the GLUT3 (coding 
for the main membrane transporter involved in glucose intake within neurons). 
Hexokinase has also been shown to exert an anti-apoptotic and protective effect in 
neurons. Ketamine is known to cause neuron damage. Hexokinase transcription increase 
after ketamine administration may thus represent a feedback mechanism to prevent 
neurotoxicity induced by this compound.  
Acute ketamine has been described to increase dopamine release in striatum (Iasevoli et 
al. 2007) while subchronic ketamine appears to induce dopamine sensitization (Becker 
et al. 2003). According to these data, in our study we have found that acute ketamine 
reduces D1R expression. D1R are the main postsynaptic excitatory dopamine receptors. 
Increased dopamine release induces a hyperstimulation of D1R and thus a condition of 
postsynaptic hyperdopaminergia. Reduction of D1R expression may represent a 
mechanism to counteract this acute hyperdopaminergia. Subchronic ketamine increases 
dopamine D2R and DAT expression, which may represent a mechanism to reduce 
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dopamine turnover and synthesis and ultimately dopamine release; and to reduce 
dopamine levels in the synaptic cleft. Thus, also these molecular changes may reflect a 
feedback mechanism to avoid hyperdopaminergia.  
However, the molecular changes induced by ketamine, and by the similar compound 
MK-801, are straightly divergent from those induced by memantine, another NMDA-R 
antagonist that has been observed to have pro-cognitive effects and that has been 
proposed as add-on agent to antipsychotics. 
Subanaesthetic doses of ketamine are known to induce a complex psychotic state in 
humans. Acute ketamine has been demonstrated to induce a worsening of BPRS scores 
in schizophrenic individuals (Lahti et al. 2001). Subchronic ketamine administration has 
been described to induce both positive and negative symptoms of psychosis, perceptual 
alterations and an impairment in several cognitive tasks (Krystal et al. 1994). Moreover, 
ketamine has been shown to affect metabolic parameters in humans. Regional cerebral 
blood flow has been found altered in limbic regions of schizophrenic individuals 
undergoing ketamine exposure (Lahti et al. 1995). Brain glucose metabolic rate in CNS 
has been found affected in several cortical regions and associated with psychopathology 
in healthy volunteers administered with ketamine (Vollenweider et al. 1997).  
Nonetheless, little is known about molecular changes occurring as a consequence of 
ketamine administration and that may resemble the molecular perturbation taking place 
in psychosis pathophysiology. The studies carried out and described herein allows to get 
insights into these issues and to provide spatial and temporal profiles of molecular 
changes elicited by ketamine administration to rats. It appears that ketamine may trigger 
a complex network of molecular adaptations, involving the glutamate and the dopamine 
systems and glucose metabolism. However, the topography of molecular changes seems 
to be peculiar for each system. Acute ketamine-mediated dopamine perturbation has 
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been described to trigger gene changes in the striatum only, while chronic perturbation 
by ketamine appears to induce changes in the midbrain but not in the striatum. No 
significant changes in dopamine genes have been recognized in the cortex. This specific 
pattern is consistent with the view that acute ketamine may trigger postsynaptic 
adaptations, while chronic ketamine may induce presynaptic feedback mechanisms to 
occur. Subcortical hyperdopaminergia has been related to positive symptoms of 
psychosis, that have been described with ketamine (Lahti et al. 1995). In opposition to 
what observed for dopamine receptors and dopamine transporter gene expression, the 
transcription of genes implicated in neuronal activation and glutamate signaling is 
prominently affected in cortical regions in the present study, although a previous study 
has also described a modulation of glutamatergic genes in ventral striatum by ketamine 
(Iasevoli et al. 2007). This pattern is consistent with the view that both glutamate and 
cortical impairment may be implicated in cognitive failure in psychosis that has also 
been described with ketamine (Krystal et al. 1994). Moreover, ketamine administration 
to rodents has been reported to induce several neuropathological lesions in cortical 
regions (Carlsson and Svensson 1990; Tiedtke et al. 1990; Riederer et al. 1991; Schmidt 
et al. 1991). Toxicity on cortical neurons has been hypothesized as the ultimate and 
diseases-inducing step of the NMDA-R hypofunction hypothesis of psychosis 
pathophysiology, that has been proposed also taking in account human and animal 
studies on behavioral, biochemical and histopathological correlates of ketamine 
administration (Allen and Iversen 1990; Olney et al. 1991; Sharp et al. 1994). In 
agreement with these observations and consistent with the data deriving from the study 
of glutamatergic genes, we have described that ketamine may strongly affect the 
expression of two key genes (i.e.: Hk1 and GLUT 3) of brain glucose metabolism in 
several cortical regions. These observations are consistent with early human studies on 
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alterations of cerebral metabolic rates by the compound (Vollenweider et al. 1997). 
Moreover, Hk1 has anti-apoptotic activity. The strong increase of Hk1 expression by 
ketamine in the cortex may also imply that ketamine exposure activates anti-apoptotic 
mechanisms to prevent the toxic neuronal damage that has been described with this 
agent. Intriguingly, memantine, a partial agonist/antagonist at NMDA-Rs, has anti-
apoptotic and pro-cognitive potential. Albeit acting as a NMDA-R antagonist in some 
cases, in our experiments memantine induces different and somewhat opposite 
molecular changes when compared to the fully NMDA-R antagonists ketamine and 
MK-801. Memantine-induced changes are prevalent in cortical regions as in the case of 
ketamine, suggesting that the fine-modulation of NMDA-R activity, even in the same 
brain regions, may activate divergent intracellular pathways and may give raise to 
divergent biological and, perhaps, behavioral consequences, possibly explaining the 
divergent clinical outcomes of these compounds.   
The overall conclusion that stems from the different paradigms investigated in this 
study and based on subanaesthetic ketamine administration model of psychosis in rats is 
that multiple changes in gene expression occur after NMDA-R-blockade in cortical and 
subcortical regions and affect the transcription of genes involved in glucose metabolism 
and dopamine-glutamate interaction. These results may represent an initial insight into 
the molecular basis of metabolic and neurotransmitter changes that have been reported 
in vivo in schizophrenics patients as well as in normal subjects after ketamine 
administration. More studies are warranted to explore the relationship between the 
perturbation of dopamine–glutamate interaction and glucose metabolism in the brain 
using ketamine and other NMDA–R non competitive antagonists as animal models of 
psychosis-like disorder. 
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